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Protein quality control systems (PQC), i.e. UPS and aggresome-autophagy pathway, 
have been suggested to be a promising target in cancer therapy. Simultaneous 
pharmacological inhibition of both pathways have shown increase efficacy in various 
tumors, such as ovarian and colon carcinoma. Here, we investigate the effect of 
concomitant inhibition of 26S proteasome by FDA-approved inhibitor Bortezomib, and 
HDAC6, as key mediator of the aggresome-autophagy system, by the highly specific 
inhibitor ST80 in rhabdomyosarcoma (RMS) cell lines. We demonstrated that 
simultaneous inhibition of 26S proteasome and selective aggresome-autophagy pathway 
significantly increases apoptosis in all tested RMS cell lines. Interestingly, we observed 
that a subpopulation of RMS cells was able to survive the co-treatment and, upon drug 
removal, to recover similarly to untreated cells. In this study, we identified co-
chaperone BAG3 as the key mediator of this recovery: BAG3 is transcriptionally up-
regulated specifically in the ST80/Bortezomib surviving cells and mediates clearance of 
cytotoxic protein aggregates by selective autophagy. Impairment of the autophagic 
pathway during the recovery phase, both by conditional knock-down of ATG7 or by 
inhibition of lysosomal degradation by BafylomicinA1, triggers accumulation of 
insoluble protein aggregates, loss of cell recovery and cell death similarly to stable short 
harpin RNA (shRNA) BAG3 knock-down. 
Our results are the first demonstration that BAG3 mediated selective autophagy is 
engaged to cope with proteotoxicity induced by simultaneous inhibition of constitutive 
PQC systems in cancer cell lines during cell recovery. Moreover, our data give new 
insights in the regulation of constitutive and on demand PQC mechanisms pointing to 






1.1. The Protein Quality Control Systems. 
Cellular homeostasis is achieved by a complex and tightly regulated serial of 
constitutive and inducible pathways which control the correct execution of cell cycling 
by mitigating potentially toxic events, such as DNA and organelle damaging and 
protein misfolding [1-3]. In order to maintain cellular homeostasis, the correct 
translation, folding and degradation of proteins is crucial (Figure 1): to this end, 
eukaryotic cells have developed a network of constitutive and inducible pathways 
which are in charge to control protein homeostasis in order to avoid proteotoxic stress 
which can eventually trigger apoptosis and/or insurgence of disease [4]. The ER 
(Endoplasmatic Reticulum) is the main sensor of protein misfolding in eukaryotic cells 
[5]. Linear newly translated proteins are folded in the ER by chaperones and co-
chaperones complexes in order to decrease the exposure of hydrophobic residues. 
Hydrophobic residues are prone to unspecific binding towards proteins leading to the 
impairment of their correct functions. When accumulation of misfolded proteins occurs, 
sensors present in the ER, such as Grp78, recognize and bind the exposed hydrophobic 
residues and induce a pro-survival response known as unfolded protein response (UPR) 
[5]. UPR mediates the decrease of CAP-dependent mRNA translation and the induction 
of chaperones and co-chaperones in order to increase the correct protein folding. 
Moreover, UPR increases protein degradation via proteasome and autophagy by the 
induction of key components of those degradative processes [6]. When misfolded 
proteins accumulation is prolonged or acute, the UPR response switches from a pro-
survival to a pro-death pathway, mainly by the induction of apoptosis [7, 8]. In this 
scenario, the degradation of unfolded and misfolded proteins plays a key role in protein 
quality control (PQC) in order to avoid induction of cell death.  
Constitutive PQC is manly taken on by two system: the ubiquitin proteasome system 
(UPS) and the autophagy-lysosomal pathway [9]. Linearized misfolded proteins are 
generally degrade by the UPS; larger structures, such as aggresomes, protein aggregates 
or p62-bodies, are cleared via the selective autophagic machinery. The interplay 
between these two systems enables cells to adapt to acute and chronic proteotoxicity by 
increasing the activity of one or both pathways: this crosstalk plays a crucial role not 
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only in the maintenance of healthy cells and tissues, but also it increases tumor cell 
survival and drug-induce resistance [10, 11].  
 
Figure 1: The PQC systems [12].  
Unfolded proteins are recognized by chaperones which mediate the correct folding process; when folding is incorrect, misfolded 
proteins can either be linearized, ubiquitin-tagged and degraded by the UPS, or form larger structures (protein aggregates) which are 
cleared by the autophagy-lysosome system 
 
1.1.1. The UPS. 
In eukaryotic cells, the UPS is in charge of the ubiquitylation, degradation and turnover 
of many regulatory and structural proteins. UPS is divided in two major steps: 1) 
protein ubiquitylation which target the tagged protein to degradation, 
compartmentalization or signaling; and 2) protein degradation mediated by the 
proteasome [13].  
 
1.1.1.1. Protein ubiquitylation. 
In order to target unfolded, regulatory or damaged proteins towards degradation and 
signaling, a tightly regulated ATP-dependent series of events need to be performed: 
final goal of these events is to tag the protein of interest with mono- or poly-ubiquitin 
chains which will serve as a regulatory signal for proteins fate [14]. The identification 
of ubiquitin as the covalently attached degradation signal of proteins was delineated in 
the early 1990s; in the last twenty years a great amount of work has been done to 
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understand in detail the regulation and biological relevance of this process with 
particular emphasis on its implication on pathology [15]. In a simplify model, ubiquitin 
needs to be activated by a two step ATP-dependent reaction mediated by a family of 
enzymes known as E1 ubiquitin-activating enzymes. Final product of the reaction is a 
thioester linkage between the ubiquitin and the E1 enzyme [16]. Second, ubiquitin is 
transferred to the active cysteine site of an ubiquitin-conjugating enzyme E2: a single 
E1 can selectively transfer ubiquitin to dozen of E2 amplifying, in this way, the 
reaction. The specificity of the substrate which has to be ubiquitinated is mediated by 
the third step of the protein ubiquitylation pathway: one of the hundreds of E3 
ubiquitin-protein ligases codified in the human genome will act as a substrate-
recognition enzyme leading to the formation of a covalent bond between a lysine 
residue of the target protein and the C-terminal glycine of the ubiquitin [16]. Recently, a 
fourth class of ubiquitin ligases has been discovered: the E4-ligase family seems to be 
responsible for the elongation of the ubiquitin chains while, the E3-ligase family mainly 
mediates mono- or multi-ubiquitylation of the substrate [17]. A growing amount of 
evidences [14] demonstrate that proteins fate depend on the lysine residue involved in 
ubiquitylation and on the presence of a polyubiquitin chain versus multiple 
monoubiquitin chains. As a general concept, polyubiquitination on Lys11, Lys29, and 
Lys48 residues is considered to target substrate to degradation, while 
monoubiquitylation on Lys63 generally leads the tagged protein towards the lysosomal 
pathway [18].  
 
1.1.1.2. The Proteasome. 
When proteins are specifically ubiquitin-tagged to degradation, the cytosolic 
multisubunit complex, known as proteasome, is engaged to mediate proteolysis of the 
substrate in an ATP-dependent manner. Proteasome is composed of three main 
subunits: a catalytic core particle (CP) and two regulatory particles (RPs) [19]. The CP, 
also known as 20S proteasome, is a barrel made of two outer -rings and two inner -
rings: the inner -rings contain the catalytically active threonine residues which are 
associated to caspase-like, trypsin-like and chymotrypsin-like activity and are therefore 
responsible for proteins proteolysis [19]. Crystallography structural studies of the CP 
demonstrate that the active cavity of the 20S proteasome is generally closed in cells, in 
order to prevent unregulated degradation of proteins: the RPs, which assemble 
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symmetrically on the two ends of the CP, are necessary for selective protein 
degradation by recognition of the ubiquitin chains attached to the substrate. Moreover, 
RPs promote substrate unfolding and translocation into the CP [20]. The assembly of 
the active proteasome complex, composed by one CP with two RPs and also known as 
26S proteasome, is of crucial importance for the maintenance of protein homeostasis: it 
has been reported that 0.5% of all genes on the human genome codify for proteasome-
interacting proteins (PIPs) needed for the correct regulation and assembly of the 26S 
proteasome [19]. Although the synthesis of proteasome components is constitutively 
ongoing, induction of proteotoxicity, by pro-oxidant stress or pharmaceutical 
proteasomal inhibition, leads to induction of proteasomal genes transcription [21]. Nrf1 
(Erythroid-derived 2-related factor 1) has been proposed as the key mediator of this 
induced transcription: upon normal condition Nrf1 is target towards the ER preventing 
its nuclear translocation; when proteotoxicity is enhanced, Nrf1 is post-translational 
modified and translocate to the nucleus where it stimulates proteasomal gene 
transcription, increasing protein degradation in order to cope with the induced 
proteotoxicity [21].  
 
1.1.2. The Autophagy-Lysosome System. 
The autophagy-lysosome system is an evolutionary conserved catabolic pathway 
constitutively active in cells: its dynamic characteristics and its tight regulation makes 
this system an extremely adaptable mechanism of degradation of large protein 
aggregates, organelles and virus upon normal and stress conditions [22]. The 
autophagy-lysosome system is divided into three different sub-types which share the 
dependency on lysosomes for the final degradation of the substrate: microautophagy, 
where cytoplasmic material is directly engulfed by lysosomes [23]; chaperone-mediated 
autophagy, which is a very selective process where proteins are recognized by 
chaperone HSP70 (Heat shock protein 70) and delivered to lysosomes [24] and 
macroautophagy. Here, we will specifically talk of macroautophagy (from now on 
called autophagy) as the main type of autophagic-lysosomal system involved in PQC. 
Autophagy is a flux, dynamic process which can be divided in three steps: initiation; 
elongation and maturation; and fusion (Figure 2). All three steps of the autophagy 
pathway are tightly regulated by a class of genes known as AuTophaGy-related genes 
(ATGs) which have been primarily discovered in yeast and are conserved in mammals 
with high sequences homology [25]. In normal conditions, autophagy is maintained at 
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basal level by the key metabolic and growth sensor mTOR (mammalian target of 
rapamycin) [26]. mTOR stimulates cell proliferation and inhibits autophagy in presence 
of nutrients; upon stress conditions, such as starvation, mTOR is inhibited enabling the 
autophagy initiator ULK1(Unc-51 like autophagy activating kinase 1)-complex to 
trigger autophagy induction to finally degrade cellular macromolecules into their basal 
components, such as amino acids and lipids, and cope with stress. Furthermore, 
depletion of nutrients activates the PI3K III (Class III phosphatidylinositol 3-kinase)-
complex which is needed to increase the amount of phosphatidylinositol-3-phosphate 
inducing membrane nucleation and thereby induction of autophagy [27] (Figure 2). 
 
 
Figure 2: The autophagy-lysosome system.  
Nutrient deprivation and/or other cellular stress inhibit the negative regulator of autophagy mTOR triggering ULK1 and PI3K III 
complexes activity and induction of the isolation membrane nucleation. The E3-like conjugating systems enrich the isolation 
membrane with specific autophagy related proteins (e.g. LC3-II) and trigger membrane elongation and closure after the engulfment 
of the cytoplasmic cargo forming the autophagosome. Finally, autophagosomes fuse with lysosomes leading to autophagolysosome 
formation and digestion of the cargo. (See text for details). 
 
The origin of nucleation of the forming double membrane vesicle, known as isolation 
membrane or phagofore, is still matter of debate: some evidences support the ER or the 
mitochondria as the primary site of phagofore nucleation, other support the de novo 
synthesis of the membrane as the main mechanism engaged for phagophore formation 
[28]. When formed, the isolation membrane is then enriched with specific autophagic 
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markers derived from protein post-translational maturation mediated by two ubiquitin-
like conjugating systems: the ATG12 and the LC3 (microtubule-associated protein 
1A/1B-light chain 3) systems [29]. ATG7 plays a major role in both ubiquitin-like 
conjugation systems: in the ATG12 system, ATG7 conjugates and activates ATG12 in 
an ATP-dependent manner; then ATG7 mediates, through an ATG10 intermediate, the 
formation of a stable isopeptide bond between ATG12-ATG5 which will integrate in 
the phagofore membranes. In the LC3 system, ATG4 cuts and activates LC3 (LC3 I 
isoform); then, ATG7 recognizes LC3 I and mediates its lipidation with 
phosphatidylethanolamine (LC3 II) through an ATG3 intermediate passage [30]. LC3 II 
integrates in the inner and outer membrane of the phagofore, remaining stably attached 
to the membrane until the complete degradation of the cargo: for this reason LC3 I/II 
conversion is nowadays the most important and used marker for detection of autophagy 
[31]. Moreover, LC3 plays a crucial role in the selection of the cytoplasmic material 
which is brought to degradation [32].  
During membrane enrichment, the phagofore elongates, engulf the cytoplasmic cargo 
and close forming a mature double membrane vesicle known as autophagosome (Figure 
2). Finally, the autophagosome eventually fuses with lysosomes, forming the 
degradative compartment known as autophagolysosome, in which the engulfed cargo 
will be digest [25]. Little is known on the exact mechanism of autophagosome-
lysosome fusion: among others, the monomeric G proteins Rab7 and Rab11 have been 
reported to be necessary for autophagolysosome formation [33, 34]. Acidification of 
lysosomes is of crucial importance for the correct degradation of cytoplasmic material: 
lysosomal enzymes need an acidic environment in order to be activated and degrade the 
cargo in the autophagolysosome, permitting the maintenance of the autophagic flux. For 
this reason, inhibitors of lysosomal acidification, such as BafilomycinA1, induce 
accumulation of autophagosomes and inhibition of the autophagic pathway due to 
impaired cargo digestion and consequent flux engulfment [35].  
 
1.1.2.1. Selective autophagy of protein aggregates and aggresomes. 
Autophagy have been described as a bulk catabolic process for many years due to its 
massive induction during starvation and consequent role in supporting cell metabolic 
stress by macromolecules recycling [36]. In the last years, a mounting amount of 
evidences suggested that autophagy can be an extremely selective pathway [37]: 
autophagy selectivity is present also in yeast where the selective delivery of hydrolase 
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aminopeptidase I from the cytoplasm to the vacuole (Cvt) has served as a model to 
study the much more complex selectivity of autophagy in mammals [38]. A big step 
towards the understanding of selective autophagy mechanisms has been the discover 
and characterization of protein adaptors necessary for the specific recognition of the 
cytosolic cargo and its targeting towards the autophagosomes [39]. Several autophagic 
receptors have been described: for example, Parkin1 and Nix (BCL2/adenovirus E1B 
19 kDa protein-interacting protein 3-like) have been reported to be specific adaptors for 
selective degradation of mitochondria [40] and NDP52 (nuclear dot protein 52 kDa) is 
necessary for the selective autophagic degradation of bacteria [41]. 
In order to selectively degrade protein aggregates, a selective autophagy adaptor protein 
must fulfilled three important functions: i) a direct or indirect interaction with the 
autophagosomal protein marker LC3; ii) the capability of polymerize or aggregate and 
iii) the ability to recognize the substrates [39]. To mediate these functions, proteins 
present specific domains of interaction: based on the presence or absence of one or 
more protein-interaction domains, protein aggregate selective adaptors have been 





Figure 3: Selective autophagy adaptors for degradation of protein aggregates [42]. 
Selective autophagic adaptors for protein aggregates are classified by the presence or absence of the LC3-interacting domain (LIR) 
and the ubiquitin-recognizing domains (UBA and/or BUZ). 
 
p62 is the most studied selective autophagic adaptor for protein aggregates selective 
autophagy. p62 plays a crucial role in selective degradation of ubiquitin-positive protein 
aggregates although a role of p62 in ubiquitin-independent degradation of mutant SOD1 
(superoxide dismutase 1) in an ALS (amyotrophic lateral sclerosis) model has been 
reported [43]. The human p62 is a 440 amino acid protein with several structural 
domains: among these domains, the UBA (ubiquitin-interacting) domain, the PB1 
(Phox and Bem 1) domain and the LIR (LC3-interacting region) domain play an 
important role in autophagy [44]. The LIR domain is a conserved 11 amino acid 
sequence which allows p62, and other receptors such as NBR1 (Neighbor of BRCA1 
gene 1 protein), to directly interact with LC3 II on the nascent and maturating 
autophagosome membrane. Through the LIR domain, p62 is constantly degraded by the 
autophagic pathway, becoming one of autophagy´s main substrates: when autophagy is 
impaired, p62 protein levels rapidly accumulate and generally associate with undigested 
autophagosomes and/or ubiquitin-positive protein aggregates [45]. Concerning selective 
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degradation of aggregates, p62 plays a double role: first, thanks to its UBA domain, p62 
recognizes ubiquitin-tagged proteins and triggers protein aggregation via self 
oligomerization through its PB1 domain; second, p62 targets protein aggregates 
towards the autophagosome [46]. Protein ubiquitylation has been shown to be the 
recognition signal for autophagic degradation of protein aggregates: although protein 
aggregation per se its sufficient to trigger autophagy [47], protein ubiquitylation 
enhance aggregates formation and cargo recognition [48]. p62 preferentially binds to 
Lys63 mono-ubiquitinated chains in vitro, concordantly with proteasome preference 
towards Lys48 poly-ubiquitinated proteins [49, 50]. Phosphorylation of p62 on Ser403 
has been demonstrated to increase p62 selectivity toward ubiquitinated proteins, in 
order to clear them through autophagy [51]. This evidence points to an important role of 
p62 post-translational modifications in the aggresome-autophagy pathway in order to 
increase substrate recognition. Moreover, p62 levels are also regulated at a 
transcriptional level upon proteotoxic stress [52]. Proteasome inhibition triggers p62 
transcriptional induction by Nrf1: p62 binds Nrf1 inhibitor Keap1 (kelch-like ECH-
associated protein 1) possibly mediating its degradation through autophagy and 
stimulating a positive feedback loop by freeing Nrf1 which translocate to the nucleus 
and increases the transcription of its target genes such as p62 [53]. p62 up-regulation is 
needed by cells to stimulate protein aggregation and autophagy induction in order to 
cope with the increased proteotoxicity.  
Together with p62 and Nbr1, other protein adaptors are needed to carry out protein 
aggregates autophagic degradation (Figure 3): for example, ALFY (autophagy-linked 
FYVE protein), does not posses any ubiquitin recognition domain or LIR domain but 
can interact with p62 and mediate protein aggregates selective targeting to 
autophagosomes by stimulating protein aggregation as a scaffold protein [54]. 
Importantly, ALFY deficient Drosophila’s showed diminished life span, ubiquitin 
protein aggregates accumulation and neurodegeneration, pointing to a crucial role of 
ALFY in PQC maintenance through autophagy [55].  
 
1.1.2.2. HDAC6: a key player of selective autophagy of protein aggregates.  
Histone deacetylases (HDACs) are an important class of enzymes which regulate the 
level of protein acetylation in cells: manly these enzymes target histones in the nucleus 
modulating chromatin structure and gene transcription [56]. Also, some HDACs are 
able to modulate acetylation of non-histone proteins in the cytosol:  acetylation, 
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together with other post-translational modifications such as phosphorylation or 
ubiquitylation, cooperates to precisely regulate proteins functions and fate in order to 
maintain cellular homeostasis [57]. HDACs are divided in three classes based on their 
sequence homology with Saccaromyces cerrevisiae: HDACs class I, II and IV [58]; a 
fourth class, Sirtuins, is present only in mammals (class III) but their sequence and 
catalytic functions differ from the other HDACs classes [59]. HDACs class I, II and IV 
share the same conserved catalytic domain which consists of a 390 amino acid tube-like 
structure with two adjacent histidine residues, two aspartic residues and one threonine 
residue needed to remove an acetylic group from the specific protein substrate [60]. 
Moreover, all three HDACs classes need Zn
2+
 as cofactor. The main difference among 
HDACs classes is their cellular localization and tissue-related expression: class I 
HDACs (HDAC1, HDAC2, HDAC3, and HDAC8) are ubiquitously expressed and 
prevalently present in the nucleus, their main function is to regulate transcription acting 
as repressors [61]. Class II HDACs are tissue-specific and are divided in two 
subgroups: class IIa (HDAC4, HDAC5, and HDAC7) has both nuclear and cytosolic 
localization; moreover, the HDACs of this class share a conserved N-terminal domain 
which regulates DNA-binding and nuclear-cytoplasmic shuttling through 14-3-3 protein 
binding and phosphorylation [62]. Class IIb (HDAC6 and HDAC10) are cytosolic 
proteins: they possess two functional catalytic domains and are involved in 
deacetylation of cytosolic proteins regulating a huge range of cellular processes such as 
migration, cell proliferation and apoptosis [63]. Class IV HDACs (HDAC11) is located 
in the cytoplasm and is the less studied HDAC´s class: recent reports suggest its 
involvement in the regulation of the immune system [64]. 
HDAC6 is a unique HDAC protein due to the presence of an ubiquitin-binding domain 
(BUZ) in its sequence (Figure 3) which plays a crucial role in PQC. In contrast with 
p62 UBA domain, the BUZ domain needs Zn
2+
 as cofactor: both, UBA and BUZ 
domains, are able to bind to mono-ubiquitin as well as poly-ubiquitin chains in vitro, 
although specific ubiquitin recognition and interaction are different between the two 
domains [65]. HDAC6 is a key regulator of several cellular processes [63]; in PQC, 
HDAC6 is involved in two crucial steps of the selective degradation of protein 





Figure 4: HDAC6 is a key player of protein aggregates selective autophagy.  
HDAC6 is needed in the aggresome-autophagy system in two different steps: 1) HDAC6 mediates aggresome formation by dynein 
transport on microtubules; 2) HDAC6 recruits a cortactin network to mediate autophagosome-lysosome fusion. 
 
HDAC6 is able to recognize misfolded and unfolded ubiquitin tagged proteins through 
its BUZ domain; then, HDAC6 triggers proteins agglomeration and dynein transport 
along the microtubules towards the MTOC (microtubule organizing center) by 
deacetylation of -tubulin in order to form aggresomes [66]. Upon proteotoxic stress, 
protein aggregate formation is stimulated in cells as a cytoprotective mechanism [66]: 
protein aggregates are less reactive compared to unfolded and misfolded proteins 
towards unspecific binding to other proteins and are more prone towards degradation by 
autophagy. In fact, protein aggregation stimulates autophagy per se: p62 interacts with 
protein aggregates and aggresomes leading to specific cargo recognition by the 
autophagosome [44, 51]. Moreover, protein aggregates and aggresomes are restrict in 
proximity of the MTOC, near the nuclear membrane, in order to decrease casual 
protein-protein interaction and, by this, toxicity. HDAC6 deficiency triggers increase 
formation of non-perinuclear protein aggregates and increase cell death upon 
proteotoxic stimuli, such as MPP(+) (1-methyl-4-phenylpyridinium), compared to 
control cells due to HDAC6-deficient cells incapability in forming complete 
cytoprotective aggresomes [67, 68]. Also, HDAC6 is needed to mediate lysosome-
autophagosome fusion by recruitment of a cortactin network which is specifically 
needed for selective degradation of protein aggregates by autophagy but dispensable for 
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bulk autophagy triggered by starvation [69]. The catalytic activity of HDAC6 is needed 
for both autophagy-related functions: protein aggregates/aggresomes formation and 
autophagosome-lysosome fusion.  
In conclusion, HDAC6 plays a crucial role in the aggresome-autophagy system by 
supporting the formation of the specific autophagic cargo – protein aggregates, 
aggresomes- and by mediating autophagosome-lysosome fusion and cargo degradation 
via remodelation of the cytoskeleton – through the recruitment of the cortactin network.     
 
1.1.3. The on demand PQC system: the role of BAG3 mediated autophagy.  
Basal protein degradation homeostasis is controlled by the constitutive PQC systems, 
UPS and HDAC6 mediated selective aggresome-autophagy system; upon increase 
proteotoxicity, such as pharmaceutics inhibition of proteasome or aging, on demand 
PCQ pathways are activated in order to guarantee an adequate level of protein 
aggregates clearance in order to decrease cytotoxicity [70]. Co-chaperone BAG3 plays 
a key role in mediating the induction and accomplishment of on demand selective 
autophagy of protein aggregates upon acute and chronic proteotoxic conditions [71]. 
BAG3 is part of the BCL2-associated athanogene (BAG) protein family (BAG1-6) 
which share the conserved 110-124 amino acid BAG domain responsible for the ATP-
dependent interaction of these proteins with HSP70 [72]. In addition to the BAG 
domain, BAG3 possess a WW domain and a proline-rich domain (Figure 3) which 
mediate the interaction with other proteins, apart from HSP70 [73]. As a selective 
adaptor for the aggresome-autophagic pathway, BAG3 doesn´t possess neither a LIR 
nor a ubiquitin-interacting domain: BAG3 mediates selective autophagy by forming a 
complex with the molecular chaperone HSPB8 (heat shock protein beta-8) which is 
essential for autophagy induction upon proteotoxic stress [74, 75]. Moreover, BAG3 
stimulates substrate transfer from HSP70 to the dynein motor complex, acting as a 
nucleotide-exchange factor, thereby facilitating the dynein-mediated retrograde 
transport of misfolded proteins towards the MTOC to form aggresomes [76]. Finally, 
BAG3 is able to interact with p62: through this interaction, BAG3 controls the 
sequestration of aggresomes and protein aggregates into the forming autophagosome 
[77]. Recently, BAG3 has been found to control protein folding by interaction with the 
cytosolic chaperonin CCT (chaperonin containing TCP-1) [78] underlining the 
importance of BAG3 in PQC from the folding step to the degradation step of misfolded 
and unfolded proteins.  
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BAG3 is poorly express in the majority of healthy young tissues [77], upon stress such 
as oxidants, serum deprivation or proteasome inhibition, BAG3 is transcriptionally up-
regulated through HSF1(heat shock transcription factor 1) [79]. Apart from its key role 
in selective degradation of protein aggregates through autophagy, BAG3 is engaged to 
regulate several others cellular process such as the development of the central nervous 
system [80], cell migration [81] and apoptosis [82].   
 
1.1.4. Crosstalk between PQC systems. 
PQC systems interplay is a key regulatory mechanism necessary for the correct protein 
degradation and homeostasis. Several transcription factors are responsible for the 
induction of the key mediators of the UPS and of the aggresome-autophagy system in 
order to increase their activity upon proteotoxic stress (Figure 5).  
 
Figure 5: PQC systems interplay. 
Misfolded proteins are direct to proteasomal degradation by BAG1/HSP70 complex and to the autophagy system by HDAC6. When 
proteotoxic stress occurs, the induction of several transcription factors and genes (red arrows) leads to increase activity of 
constitutive and on demand PQC systems. (See text for details). 
 
Upon normal condition, the proteasome is able to functionally degrade misfolded 
proteins; when proteotoxic stress occurs, as consequence of stimuli such as xenobiotics 
or pro-oxidant compounds, the level of misfolded proteins rapidly increases leading to 
proteasome overloading [83]. To prevent the accumulation of toxic misfolded and 
unfolded proteins, the transcription factor Nrf1 is target from the ER to the nucleus in 
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order to induce the transcription of the PIP genes which mediate the increase assembly 
of new functional proteasomes [21]. Proteasome inhibition has been largely described 
to induce the up-regulation of the autophagic pathway: proteasome inhibitors, such as 
Bortezomib or MG132, have been shown to increase the autophagic pathways in 
several tumor cell lines [10]. On demand PQC systems are mainly engaged during 
chronic and acute proteotoxic stress: it is not surprising that the key mediator of the on 
demand selective aggresome-autophagy pathway, BAG3, is transcriptionally induced 
upon proteasome inhibition [84]. Gamerdinger and colleagues have elegantly showed in 
a model of aged cell line (I90) that BAG3 induction is tightly related to the decrease of 
another BAG family member, BAG1, which is mainly engaged in delivering misfolded 
proteins towards proteasomal degradation [77]. In young cells, BAG1 mediates protein 
degradation through its binding to HSP70; when cells are aging, proteasome activity 
decreases triggering transcriptional inhibition of BAG1 and increase transcription of 
BAG3 (mechanism known as: BAG1/BAG3 switch) leading to increase protein 
degradation through selective autophagy [77].  Accumulation of misfolded proteins 
triggers BAG3 up-regulation also via HDAC6 [85]: in non-stress conditions, HDAC6 is 
sequestered by the ER ATPase VCP/p97 (97-kDa valosin-containing protein) to form a 
complex with HSP90 and HSF1 preventing the latter to translocate to the nucleus and 
induce the transcription of its target genes, for example BAG3. When misfolded 
proteins are accumulated, HDAC6 binds them and dissociates from the complex, 
freeing HSF1 and consequentially leading to BAG3 induction (Figure 5).  
Another important sensor and modulator of UPS and selective autophagy interplay is 
p62 [86]. p62 gene transcription is mediated by the transcriptional factor Nrf2: upon 
proteasomal inhibition Nrf2 translocation to the nucleus is enhanced, promoting p62 
transcription and translation. As a consequence, p62 accumulates in the cytosol 
mediating protein aggregation and recognition by the autophagic pathway [87]. On the 
contrary, upon autophagy inhibition, cytosolic p62 protein levels increase as a 
consequence of its impaired degradation: elevated cytosolic p62 protein levels lead to 
proteasomal inhibition and trigger the induction of PQC systems by enhancing the 
transcription of proteasomal genes, such as PIPs, and regulators of selective and bulk 




1.2. Cancer.  
Cancer, also known as tumor or malignant neoplasm, is one of the first cause of death 
worldwide: in 2008, 12.7 millions of people were diagnosed with cancer and, of these, 
more than 50% died [88]. Cancer is a wide and very different set of diseases which can 
potentially occur in every cell type of an organism; this wide heterogeneity makes this 
malignancy very difficult to diagnose and treat. In general, cancer can be described as a 
deregulated growth of single or multiple cells which acquire specific characteristics, 
such as motility or angiogenesis, which lead to impairment of the normal homeostasis 
of the tissue, eventually causing death of the organism. It is largely accepted that all 
tumor types develop as consequence of mutations in the DNA. Two different kinds of 
mutations can occur in the genes: i) the “gain of function” mutations, where the lesion 
in the gene hyper-activates the transcription or the activity of the related protein [89]; 
and ii) “loss of function” mutations, where the gene involved is silenced, or the protein 
encoded by the specific gene is not anymore functional [89]. Genes involved is cell 
cycling regulation, DNA damage and in the induction of apoptosis are generally targets 
of “loss of function” mutations: as an example, p53, one of the key sensors of DNA 
damage, is found mutated in 50% of diagnosed cancers [90]. Mutated p53 is unable to 
inhibit cell proliferation upon DNA damage and, in case the damage is too pronounce, 
to induce cell death. In neuroblastoma cell lines, “loss of function” mutations of the 
effectors of apoptosis, the caspase family, have been reported [91]. 
“Gain of function” mutations occur in genes which regulate the response to cell growth 
stimuli: growth factors receptors, such as EGF (epidermal growth factor) receptors, 
have been reported to be mutated in lung cancer, promoting cell proliferation [92]. The 
tyrosine-kinase RAS (Rat sarcoma associated protein), which plays a key role in 
modulating cell growth, has been reported mutated in different tumors, such as 
melanoma, triggering enhanced survival and resistance toward treatments [93].  
Due to their intense proliferation and high mutation rates, cancer cells are generally 
more incline to accumulate mutated and truncated proteins as a result of enhance 
uncontrolled DNA synthesis, nutrient starvation or oxidative stress which generate 
increase levels of unfolded and misfolded proteins in the cytosol, triggering constitutive 
activation of the UPR [94]. Enhancement of pro-survival pathways is a key feature of 
many tumor types: among others, the NF-B (nuclear factor kappa-light-chain-enhancer 
of activated B cells) pathway plays a master role in cell proliferation and survival of 
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many tumors [95]. Briefly, the NF-B pathway is activated in response to exogenous 
stimuli, e.g. TNFtumor necrosis factor ), or endogenous cellular stress, i.e. ROS 
(reactive oxygen species). The canonical activation of the pathway (Figure 6) involves 
the phosphorylation of IB (inhibitor of NF‐B), an inhibitor subunit which prevents 
the nuclear translocation of the transcriptional factors RelA (transcription factor p65) 
and p50 and consequent IB proteasomal degradation. After IB degradation, RelA 
and p50 can translocate to the nucleus, bind the DNA and enhance transcription of 
several pro-survival genes which sustain tumor growth [96].   
 
Figure 6: The canonical NF-B pathway.  
Inactive IB-p50-RelA cytosolic complex is activated by phosphorylation of IB and its further ubiquitylation and proteasomal 
degradation. RelA and p50 are able to translocate to the nucleus and induce NF-B target genes. 
 
Although, NF-B pathway is mostly involved in tumor survival, some recent reports 
suggest that the activation of NF-B is enhancing cell death in glioblastoma cell lines 
upon TRAIL treatment [97] 
 
1.2.1. Rhabdomyosarcoma. 
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. This 
tumor likely originates from an imbalanced differentiation process of the precursor cells 
of the skeletal muscle [98]: RMS cells are unable to reach terminal differentiation 
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exhibiting sustained proliferation, and muscle-specific markers of fetal muscle 
development such as MyoD (Myogenic regulatory factor D) and Vimentin [99].   
RMS tumors are divided in three histological subgroups: the embryonal subgroup 
(ERMS), which is the most common kind of pediatric RMS; the alveolar subgroup 
(ARMS), which is more aggressive and less common than the ERMS subgroup; and the 
rare adult variant of RMS known  as pleomorphic variant rhabdomyosarcoma (PRMS) 
[100]. Little is known of the genetic aberrations which drive the insurgences of the 
different pediatric RMS: ERMS has no specific gain or loss function mutations 
associated with the insurgence of the tumor; in contrast, 85% of ARMS diagnosted 
tumors are associated with the translocation of genes encoding the transcriptional factor 
FOXO1A (forkhead box protein O1) with PAX-3 or PAX-7 (paired box proteins -3 and 
-7) resulting in FOXO1A uncontrolled transcriptional activity with consequent 
induction of proliferating genes such as MDM2 (Mouse double minute 2 homolog), 
MYCN (v-myc myelocytomatosis viral related oncogene, neuroblastoma derived) and 
GLI (Glioma-associated oncogene family zinc finger) [101]. Moreover RMS is 
associated with mutation of growth pathways, such as RAS (mainly NRAS or KRAS 
mutations), which in the last years have been associated with increased basal autophagy 
in different tumor types [102]. Immortal RMS cell lines differing for chromosomal 
background and histological subgroups are now available: for example, the RMS RD 
embryonal cell line possess a NRAS mutation [103], while the alveolar RMS RMS13 
cell line is wild type for RAS but shows FOXO1-PAX3 fusion gene overexpression 
[104] 
Currently, the therapy used for RMS patients involves surgery, and usually radiotherapy 
followed by chemotherapy- commonly a combinatory treatment of vincristine and 
dactinomycin together with alkylating agents, either cyclophosphamide or ifosfamide 
[105]. Despite the therapeutic efforts, RMS prognosis remains poor: for this reason, the 
study of novel targets and therapeutic agents which can improve RMS patients’ 
outcome is of crucial importance. In the last years, the development of animal models 
for RMS has improved research on this topic [106]. Recently, inhibitors of the Hedgeog 
pathway have been described to sensitize RMS cell lines toward cell death [107]; 
moreover, co-treatment with PI3K/Akt/mTOR inhibitors and RAS/MEK/ERK 




1.3. PQC in cancer. 
PQC systems have been proposed to be an interesting target in cancer therapy [109]. 
Drugs which selectively target 26S proteasome or key components of the aggresome-
autophagy system, such as HDAC6, have been tested in vitro and in vivo and showed 
encouraging results in different types of tumors [110, 111]. Bortezomib is the first 
selective 26S proteasomal inhibitor which has been approved for clinical use by the 
FDA (Food and Drug Administration) for multiple myeloma treatment. Bortezomib is a 
N-protected dipeptide (Pyz-Phe-boroLeu) with a boron atom at the C-terminus [112]: 
boron interacts specifically with the catalytic subunit of the 26S proteasome and 
reversibly inhibits it triggering accumulation of short living proteins, pro-apoptotic 
regulators and misfolded and unfolded proteins [112]. Single treatment with 
Bortezomib triggers apoptosis in many cancer models; nevertheless, inhibition of 
proteasome causes induction of the autophagic branch of PQC leading to the selection 
of tumor cells which are resistant towards Bortezomib treatment [113]. 
HDACs have been reported to play a key role in cancer promotion and maintenance 
[114]: particular interest has been given to the synthesis of selective HDAC6 inhibitors 
due to its key role in modulation of many cellular pathways, mostly the aggresome-
autophagy system. Several kind of specific HDAC6 inhibitors have been synthetized 
[115] and tested, showing induction of apoptosis in different cancer models, such as 
ovarian carcinoma [116]. ST80 is a newly synthetized HDAC6 inhibitor: this 
hydroxamate shows 31-fold more selectivity towards HDAC6 inhibition compared to 
HDAC1 inhibition [117].  
As a consequence of the strong interplay between PQC systems (Figure 5), single 
treatment towards one of the constitutive PQC pathways determines a poor tumor 
apoptosis outcome due to increase activation of the other PQC system and consequent 
induced-resistance towards the treatment [10]. To overcome this acquired resistance, 
co-treatment strategies have been proposed: apoptosis induction by Bortezomib is 
significantly enhanced when the drug is used concomitantly with autophagic interfering 
drugs, such as chloroquine [118], or HDACs inhibitors [119]. Also, co-treatment 
strategies allow to decrease the concentration of drugs used, possibly diminishing off-
target effects on healthy cells, and toxic side effects of the therapy on patients.  
Little is known on the role of on demand BAG3 mediated autophagy in response to 
treatments in tumors. BAG3 protein expression has been found enhanced in different 
tumors, such as leukemia [120] and glioblastoma [121] and BAG3 knock-down has 
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been reported to increase cell death upon drug treatment [122]. It is still not clear if co-
treatments which affect the constitutive PQC systems can induce resistance mechanisms 
based on BAG3 similarly to single treatments which increase the efficiency of 
proteasome or autophagy when the other PQC system is impaired.  
Rhabdomyosarcoma has been found to be sensitive towards Bortezomib single agent 
treatment [112]: Bortezomib triggers apoptosis and induces accumulation of misfolded 
ubiquitin tagged proteins in the cytosol. According to these data, rhabdomyosarcoma 
cell lines are a suitable model to study the effects of simultaneous inhibition of 
proteasome and HDAC6-mediated aggresome-autophagy system.           
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2. Aim of the Study 
 
Increasing the efficiency of cancer treatments is one of the primary goals of 
translational cancer research. On one hand, efforts have been made in order to find a set 
of specific druggable targets which can be selectively exploited to kill tumor cells; on 
the other hand, the high rate of mutations occurring in tumors leads to high level of 
acquired resistance towards drugs. Constitutive protein quality control systems (PQC), 
i.e. proteasome and the selective aggresome-autophagy pathway, have recently been 
described as interesting targets to selectively induce apoptosis in various tumor entities 
[111]: for example, inhibitors of proteasome, such as Bortezomib, showed encouraging 
results in trial studies of myeloma patients [123]; and inhibitors of HDAC6, a key 
component of the aggresome-autophagy system, show toxicity toward tumors in 
preclinical studies [124]. Single agent treatment against one of the two main branches 
of PQC often triggers the compensatory induction of the other PQC branch, leading to 
acquired tumor resistance toward the treatment [10]. Combinatory treatment strategies 
have been proposed to overcome this resistance, showing synergism in a various 
number of tumor types [125, 126]. 
Here we aimed to investigate the effect on cell death of concomitant pharmacological 
inhibition of constitutive PQC (proteasome and aggresome-autophagy system) by 
Bortezomib and HDAC6 catalytic inhibitor ST80 in rhabdomyosarcoma cell lines. 
Moreover, we focused our attention on the insurgence of inducible resistance 
mechanisms triggered by the co-treatment which would allow ST80/Bortezomib 








3.1.1. Cell lines 
 
3.1.1.1. Rhabdomyosarcoma and fibroblast cell lines 
Cell line Provider 
BJ American Type Culture Collection 
RD American Type Culture Collection 
RMS13 American Type Culture Collection 
TE671 American Type Culture Collection 
 
3.1.1.2. Virus packaging cell lines 
Cell line Provider 
HEK293T American Type Culture Collection 
RetroPack™ PT67 Cell line Clontech Laboratories/ BD Biosciences 
 
3.1.2. Cell culture reagent 
Reagent Provider 
Doxycyclin Santa Crutz Biotechnology 
Dulbecco's modified eagle medium 
(DMEM) 
Gibco 
Fetal Calf Serum (FCS) Invitrogen 
HEPES Gibco 
MEMα, GlutaMAX™, no Nucleosides Invirtogen 
PBS (Dulbecco’s phosphate buffered 
saline) (1x) 
PAA Laboratories 
Penicillin/ Streptomycin (100x) PAA Laboratories 
Puromycin PAA Laboratories 
RPMI Medium 1640(1x) - GlutaMAX™-I Invitrogen 
Sodium pyruvate (100x) Gibco 
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Trypan blue Invitrogen 
Trypsin/EDTA solution Gibco 
Zeocin InvivoGen 
 
3.1.3. Apoptosis inducing agents, inhibitors 
Reagent Provider 
ABT-737 Kindly provided by Abbott Laboratories 
Bafilomycin A1 Sigma 
Bortezomib Purchased by Jansen-Cilag 
Lexatumumab Kindly provided by R. Humphreys 
ST80 Kindly provided by M. Jung 
TNF  Biochrom 
 
3.1.4. Protein electrophoresis and western blot reagents 
Reagent Provider 
Albumin fraction V (BSA) Carl Roth 
Ammonium persulfate Carl Roth 
Dithiothreitol (DTT) Calbiochem 
Gel blot paper  Carl Roth 
Hybond ECL 0.45 µm Amersham Bioscience 
Hyperfilm ECL Amersham Bioscience 




Nitrocellulose Membrane Amersham Bioscience 
PageRuler Plus Prestained Protein Ladder Fermentas 
Pierce® ECL Western Blotting Detection 
Reagents 
Thermo Scientific 
Protease inhibitor cocktail  Carl Roth 
PVDF Membrane Millipore 
Roentoroll HC x-ray developer TETENAL 
Rotiphorese® Gel 30 Carl Roth 
23 
 
Sodium Dodecyl sulfate (SDS) Carl Roth 
Starter for x-ray developer TETENAL 
Superfix MRP x-ray fixing solution TETENAL 
Triton X-100 Carl Roth 




3.1.5.1. Primary western blot antibodies  
(diluted in 2% BSA/PBS, 0.02% sodium azide) 
Antibody Dilution Provider 
mouse anti-GAPDH 1:5000 HyTest 
mouse anti-polyubiquitin 1:1000 Millipore 
mouse anti-α-tubulin (DM1A) 1:3000 Calbiochem 
mouse anti-β-actin 1:10000 Sigma 
rabbit anti-ATG7 1:500 AbCam 
rabbit anti-BAG3 1:1000 AbCam 
rabbit anti-Histone 3 1:1000 AbCam 
rabbit anti-IκBα 1:500 Cell Signaling 
rabbit anti-LC3 1:2000 Thermo Scientific 
rabbit anti-p62/SQSTM1 1:1000 MBL 
 
3.1.5.2. Secondary western blot antibodies  
(diluted in 5% milk/PBS-T) 
Antibody Dilution Provider 
anti-mouse infrared dye-labeled 
green 
1:10000 Li-COR Bioscience 
anti-mouse infrared dye-labeled 
red 
1:20000 Li-COR Bioscience 
anti-rabbit infrared dye-labeled 
green 
1:10000 Li-COR Bioscience 
anti-rabbit infrared dye-labeled 
red 
1:20000 Li-COR Bioscience 
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goat anti-mouse IgG conjugated 
to HRP 
1:5000 Santa Cruz 
goat anti-rabbit IgG conjugated to 
HRP 




pCFG5-IEGZ  kindly provided by B.Baumann 
pCFG5-IEGZ IκBα-S(32,36)A kindly provided by B.Baumann 
pCMV-dR8.91 Thermo Fisher Scientific 
pGIPZ-shRNAmir Thermo Fisher Scientific 
pMD2.G Thermo Fisher Scientific 
pTRIPZ-shRNAmir Thermo Fisher Scientific 
 
3.1.7. shRNA plasmids  
(provided by Thermo Fisher Scientific) 
Gene  Library reference number 
ATG7  RHS4430 
BAG3 (#1) RHS4430 
BAG3 (#3) RHS4430 
BAG3 (#4) RHS4430 
Control (Ctrl) RHS4346 
 





 1 kb DNA ladder Fermentas 
MluI enzime Fermentas 
One Shot Top 10 E.coli competent cells Invitrogen 
Restriction enzyme buffer R Fermentas 
T4 DNA Buffer Ligase Fermentas 
T4 DNA ligase Fermentas 




3.1.9. Oligonucleotides for qRT-PCR 
Name Sequence 
18S  forward (for) CGCAAATTACCCACTCCCG 
18S  reverse (rew) TTCCAATTACAGGGCCTCGAA 
BAG1 forward (for) TCACCCACAGCAATGAGAAG 
BAG1 reverse (rew) ATTAACATGACCCGGCAACC 
BAG3 forward (for) CTCCATTCCGGTGATACACGA 
BAG3 reverse (rew) TGGTGGGTCTGGTACTCCC 
TNF forward (for) ACAACCCTCAGACGCCACAT 




7900HT fast real-time PCR system Applied Biosystems 
GeneJET
TM
 Gel extraction Kit Fermentas 
peqGOLD Total RNA kit Peqlab Biotechnologie GmbH 
Pierce® BCA Protein Assay Kit Thermo Scientific 
Pure Link HiPure Plasmid Filter 
Maxiprep Kit 
Invirtogen 
RevertAid H Minus First Strand cDNA 
Synthesis Kit 
MBI Fermentas GmbH 
 
3.1.11. General chemicals 
Reagent Provider 
Bromphenolblue Carl Roth 
Crystal violet Carl Roth 




Ethanol Carl Roth 
Glycerol Carl Roth 
Glycin  Carl Roth 
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Kaliumdihydrogenphosphat (KH2PO4) Carl Roth 
Lipofectamine 2000 Invitrogen 
LysoTracker® Red CMXRos Molecular Probes 
Methanol Carl Roth 
Phenylmethylsulfonyl fluoride (PMSF) Carl Roth 
Polybrene (Hexadimethrine bromide) Sigma 
Potassium Chloride (KCl) Riedel-de Haen 
Propidium iodide Sigma 
Sodium chloride Carl Roth 
Tris  Carl Roth 
-Mercaptoethanol Merck 
 
3.1.12. Plastic material 
Material Provider 
Cell culture flasks (25 cm², 75 cm², 175 
cm²) 
Greiner Bio-One 
Collagen type 1 coated plates (24, 96-
well) 
Greiner Bio-One 
Combitips (0.5 ml, 1 ml, 2.5 ml, 5 ml, 10 
ml) 
Eppendorf 




 optical 96-well reaction 
plate 
Applied Biosystems 
Pasteur pipettes  Carl Roth 
Pipette tips (10 μl, 200 μl, 1000 μl) Starlab 
Reaction tubes (0.5 ml, 1.5 ml, 2 ml) Starlab 
Round bottom tubes (FACS tubes)  BD Biosciences 
Sterile pipettes (2 ml, 5 ml, 10 ml, 25 ml) Greiner Bio-One 
Syringe B.Braun 
Tissue culture dishes (6, 10 cm) Greiner Bio-One 
Tissue culture plates (24-well) Starlab 






7900HT fast real-time PCR system Applied Biosystems 
Analytical balance 770 KERN 
Autoclave Systec V150 Systec 
Balance 440-47N KERN 
Blotting chamber BioRad 
Cell culture incubator, MCO-20AIC Sanyo 
Centrifuge 50RS Hettich 
Centrifuge Avanti J26-XP Beckman Coulter 
Centrifuge Micro 200R Hettich 
Counting chamber (Neubauer) Marienfeld GmbH 
DNA-electrophoresis system BioRad 
Electrophoresis power supply BioRad 
FACSCanto II with FACSDIVA Software BD Biosciences 
Gel dryer (model 583) BioRad 




 imaging system Li-COR 
Microscope IX71 (light) Olympus 
Multipette® plus Eppendorf 
Nanodrop 1000 spectrometer   Peqlab 
PCR Thermocycler Eppendorf 
Pipetboy acu  Eppendorf 
Pipettes Eppendorf 
Rocking shaker CAT 
Roller mixer Ratek 
Rotator Stuart 
Sonicator H2070 Bandelin Sonplus 
Table centrifuge Carl Roth 
Thermo mixer comfort Eppendorf 
Vortex mixer Velp Scientifica 
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3.2.1. Cell culture 
Rhabdomyosarcoma cell lines and human fibroblast cell line (BJ) were kept in culture 
in RPMI 1640 (RMS13, TE671) or DMEM medium (RD, BJ) supplemented with 10 % 
fetal calf serum (FCS), 1 mM glutamine, 1 % penicillin/streptomycin and 25 mM 
HEPES. 
 
3.2.2. Generation of stable genetic modified cell lines 
 
3.2.2.1. Retroviral transduction 
Production of RMS NFB super-repressor cell lines (IB-SR) were obtained by 
transfecting pCFG5-IEGZ vector or pCFG5-IEGZ vector containing IB-S(32, 36)A 
into PT67 gamma-retroviral producer cells as previously described [127]. PT67 were 




) in penicillin/streptomycin free medium to then 
be transfected with a solution of 4 µl Lipofectamine 2000 and 4 µg plasmid DNA for 
each well. After 6 hours incubation, medium was changed and cells were grown in 
DMEM complete medium for 48 hours. PT67 virus-containing supernatant was 





) 24 hours previous infection and then spin-transduced with 3 ml supernatant 
containing 8 µg/ml polybrene at 1300 rpm for 90 min at 25°C. After 6 hours incubation, 
virus containing medium was removed and cells were selected for 2 weeks with 1 
µg/ml zeomycin. Infection efficiency was determined by western blot analysis.   
 
3.2.2.2. Lentiviral transduction (shRNA)   
For stable or inducible gene knockdown, HEK293T producer cells were transfected 
with pGIPZ-shRNAmir or pTRIPZ-shRNAmir vector using calcium phosphate 





) 24 hours prior transfection. DNA mix solution of 7.5µg 
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pGIPZ-shRNAmir or pTRIPZ-shRNAmir vector, 12.5µg pCMV-dR8.91 and 1µg 
pMD2.G in ddH2O containing 50µl of 2M CaCl2 was add to 2x HEPES buffered 
solution (HBS) for 20 minutes (transfection solution). Meanwhile, HEK293T DMEM-
complete medium was changed with fresh media containing 25µM chloroquine. 
Transfection solution was drop wise added. Medium was exchanged after 10-12 hours 
and cells were grown in fresh medium for 48 hours. Virus containing supernatant was 
filtered using a 45µm filter and then add to target RMS cells together with 8 µg/ml 
polybrene. Spin-transduction of target cells was carried on at 1300 rpm for 90 min at 
25°C. Cells were selected for 1 week with 1 ng/ml puromycin. Knock down efficiency 
was evaluated by qRT-PCR and/or western blot analysis. 
 
3.2.3. Fluorescence-activated cell-sorting (FACS) analysis 
 
3.2.3.1. Determination of apoptosis 
Apoptosis was measured by fluorescence-activated cell-sorting (FACS) analysis of 
DNA fragmentation of propidium iodide-stained nuclei as previously described [129]. 




) 24 hours previous treatment. 
At indicated time points, cells were trypsinized and washed in cold 1xPBS for 5 
minutes at 1800rpm at 4°C. After supernatant was discharged, pellets were resuspend in 
a hypotonic fluorochrome solution containing 50 µg/ml propidium iodide, 0.1% sodium 
citrate and 0.4% Triton-X 100 for at least 1 hour at 4°C. The content of hypodiploid 
DNA (sub-G1 peak) was quantified by FACS as indicator of apoptotic cell death. 
 
3.2.3.2. Determination of lysosomal acidification 
Acidification of lysosome was measured by fluorescence-activated cell-sorting (FACS) 
analysis of Lysotracker Red stained lysosomes according to manufacture instructions. 




) 24 hours previous treatment. 
At indicated time points 0.05 nM Lysotraker Red was add to the medium directly in the 
well for 10 minutes. Medium was then eliminated and cells were recovered by 
trypsinization and washed with 1xPBS for 5 minutes at 1800rpm at room temperature. 





3.2.4. Determination of cell viability and colony formation 
Cell viability was assessed by crystal violet staining of living cells. RMS cell lines were 




) and treated after 24 hours. At indicated 
time points, medium was discharged and cells were stained directly on plate with 
crystal violet solution containing 0.75 % crystal violet, 50 % ethanol, 0.25 % NaCl, 
1.57 % formaldehyde for 10 minutes. Crystal violet solution was then removed and 
stained cells were resuspended in 1% SDS. Absorbance at 550nM was measured by 
microplate reader. 
For colony formation assay, RMS treated cells were reseeded in 6-well plates as single 
cells (200 cells/well) and grown in drug free medium for 14 days. After removal of the 
medium, colonies were stained with crystal violet solution. The number of colonies was 
assessed by counting under the microscope.  
 
3.2.5. Molecular biology methods 
 
3.2.5.1. Protein extraction and quantification 
Cells were lysate in lytic buffer (30 mM Tris HCl, 150 mM NaCl, 1% Triton-X 100, 
10% Glycerol 0.5 mM, PMSF, 2mM DTT and protease inhibitor cocktail) 
supplemented with 100mM PMSF  and phosfatase inhibitors (1 mM Sodium-
orthovanadate, 1 mM -glycerophosphate, 5mM Sodium Fluoride) for 30 minutes on 
ice. After hypercentrifugation (14000 rpm, 30 minutes, 4°C), supernatant was collected. 
Protein determination of the supernatant was assessed by Pierce® BCA Protein Assay 
Kit according to manufacture instructions. 
 
3.2.5.2. Western blot analysis 
Western blot analysis was performed as described previously [129]. Briefly, equal 
amounts of proteins were diluted in 1xSDS loading buffer (TrisBase (1M; pH 6.8), 5% 
Glycerol, 1% SDS, 2mM DTT; 0.01 mg/ml Bromphenolblue) and denatureted for 5 
minutes at 96°C. Proteins were then loaded into home made polyacrylamide gels 
(resolving gel: 10% 12% 13.5% Acrylamide, 0.1% SDS, 250 mM Tris HCl pH 8.8, 
0.1% APS, 0.04% TEMED; stacking gel: 5% Acrylamide, 0.1% SDS, 125 mM Tris 
HCl pH 6.8, 0.1% APS, 0.1% TEMED). Proteins were run on the gel at constant 
voltage (100-150 V) until they reached the end of the gel. Blotting on hybond 
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nitrocellulose or polyvinylidene difluoride (PVDF) membrane was performed by 
semidry blotting system. Gel paper, gel and membranes were equilibrated in blotting 
buffer (125 mM Tris Base, 1.25 mM Glycine, 0.1% SDS, 20% Methanol) and piled on 
the anode plate. Blotting was performed with constant ampere (1 mA/cm
2
) for 1 hour or 
1 hour 40 minutes depending on the thickness of the gel. Membranes were then blocked 
in a 5% milk/PBS-T solution for 1 hour to prevent unspecific binding. Primary 
antibodies (see paragraph 3.1.5.1) were diluted in blocking solution or 2% BSA, 0.05% 
Sodium azide containing PBS-T solution and were incubated over night at 4°C. To 
avoid unspecific binding of secondary antibody, membranes were washed three times 
with 1XPBS-T and incubated 1 hour with alternatively secondary antibody conjugated 
to horseradish peroxidase (HRP) or infrared dye-labeled secondary antibodies diluted in 
5% milk/PBS-T. Specific protein signal was detected after three wash in 1xPBS-T by 
enhanced chemiluminescence (ECL) or infrared Odyssey
®
 imaging system, 
respectively. Representative images of at least two independent experiments are shown. 
 
3.2.5.3. Detection of protein aggregates: Triton-X fractionation 
Protein aggregates were detected by fractionation in Triton-X as previously described 
[130]. Cells were lysate in 2% Triton-X/1% PBS solution supplemented with proteases 
and phosphatases (100mM PMSF, 1 mM Sodium-orthovanadate, 1 mM -
glycerophosphate, 5mM Sodium Fluoride) for 30 minutes on ice. Lysate were 
centrifuged (13000 rpm, 30 minutes, 4 °C); supernatant was collected as soluble 
fraction. Pellets were resuspended in 1% SDS supplemented with proteases and 
phosphatases and sonicated for 20 second (45% intensity). Expression of ubiquitin-
positive protein aggregates was determined by western blot analysis. 
 
3.2.5.4. Detection of protein aggregates: Filter Trap assay 
Determination of protein aggregates by filter trap assay was performed as previously 
described [131]. Shortly, cells were recovered by scraping in 1XPBS and centrifuge 
1800 rpm 5 minutes at 4 °C. Pellets were resuspended in 1XPBS supplemented with 
proteases and phosphatases and sonicated twice for 20 seconds (45% intensity). After 
protein determination, equal amount of proteins were resuspended in 1% SDS and 
directly vacuum-blotted on a nitrocellulose membrane. Ubiquitin-positive aggregates 
were detected by western blot. 
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3.2.6. Generation of pTRIPZ-shRNA plasmids. 
Sub-clonation of shRNA control sequence and shATG7 sequence (see paragraph 3.1.7) 
from the pGIPZ plasmid to the doxocyclin inducible pTRIPZ plasmid was obtained by 
digestion of 8 µg pGIPZ-shRNA containing plasmid and 5 µg pTRPZ empty plasmid 
with 1 µl of XhoI and MluI restriction enzymes for 3 hours. Digestion products were 
respectively run in a homemade 0.8% and 1% agarose gel supplemented with ethidium 
bromide. Gel extraction of the correspondent DNA band from the agarose gel was 
performed with GeneJET
TM
 GEL extraction Kit according to manufacture instructions. 
250 ng of pTRIPZ and 7.5 ng of the insertion sequences were ligate with 0.5 µl of T4 
ligase enzyme for 1 hour. One Shot Top 10 E.coli competent cells were transformed 
with the ligation solution according to manufacture instructions and grown overnight. 
Plasmid extraction was performed by Pure Link HiPure Plasmid Filter Maxiprep Kit 
according to manufacture instructions.       
 
 
3.2.7. Quantitative Reverse Transcription PCR (qRT-PCR) 
Total RNA was extracted using peqGOLD Total RNA kit according to the 
manufacturere instructions. 3 µg of total RNA were used to synthetize the 
corresponding cDNA using RevertAid H Minus First Strand cDNA Synthesis Kit. 
Quantitative evaluation of selected genes (see paragraph 3.1.9) was determined by 
SYBR-Green based qRT-PCR performed by using the 7900HT fast real-time PCR 
system. Briefly, 500 ng cDNA was loaded in each well (96-well plate) with 2XSYBR-
Green solution and 10 pMol/µl of forward and reverse gene specific oligonucleotide 
primer and/or reference oligonucleotide primer 18S. qRT-PCR reaction was performed 
for 40 cycles (50 °C 2 min.; 95°C 10 min.; 95°C 15 sec.; 60°C 1 min.). Denaturation 
curves were plotted to verify the specificity of the amplified products. All 
determinations were performed in triplicate. The relative expression of the target gene 
transcript and reference gene transcript was calculated as ΔΔCt.  
 
3.2.8. Statistical analysis 
Statistical significance was assessed by Student's t-Test (two-tailed distribution, two-





4.1. A subpopulation of RMS cells is able to survive and recover upon ST80/ 
Bortezomib co-treatment.   
To investigate the potential role of concomitant inhibition of constitutive PQC systems, 
i.e. UPS and aggresome-autophagy system, we selected three different RMS cell lines 
(RD, TE671 and RMS13) and one non-transformed fibroblast cell line (BJ) and treated 
them with specific inhibitors of the two pathways. Bortezomib, commercially known as 
Valcade®, is an N-protected dipeptide which selectively and reversibly inhibits the 26S 
proteasome [132]. ST80 is a second generation inhibitor of the HDACs: this 
hydroxamates is designed in order to selectively inhibit the catalytic activity of HDAC6 
with a specificity 31.4 fold higher toward HDAC6 compared to HDAC1 [117]. We 
subject RMS cell lines to 48 hours of single or double treatment of 50 µM ST80 and/or 
three different concentration of Bortezomib; then, we measured apoptosis by 
quantification of DNA fragmentation (Figure 7). Importantly, addition of ST80 
significantly increased Bortezomib induced apoptosis in both embryonal (RD and 
TE671) and alveolar (RMS13) cell lines but showed no additional effect in non-
transformed fibroblast, pointing to some tumor selectivity. 
 
Figure 7: ST80 synergistically co-operates with Bortezomib to induce cell death in RMS.  
Cells were treated for 48 hours with 50 µM ST80 and/or Bortezomib as indicated. BJ cells were treated for 48 hours with 50µM 
ST80 and/or 20nM Bortezomib. Apoptosis was determined by FACS analysis of DNA fragmentation of propidium iodide stained 
nuclei. Three independent experiments in triplicate are shown. t-Student test was used to determine statistical significance: * 




Although we could increase cell death in RMS cell lines by ST80/Bortezomib co-
treatment, we wondered if a subpopulation of cells was able to survive the treatment 
and, upon drug removal, was able to regrowth at similar rates as the untreated or single 
treated surviving cells. To address this question we monitored cell recovery over time 
after drug removal (Figure 8). 
 
Figure 8: Experimental design for recovery studies. 
Recovery experiments were done by treating the cells with single or double treatment (BS) for 48 hours before treatment  was 
removed and cells were able to regrowth in drug free medium up to 10 days 
 
We selected two representative RMS cell lines, the embryonal RD cell line and the 
alveolar RMS13 cell line, as models for further studies. After 48 hours nearly one third 
of cells were able to survive ST80/Bortezomib co-treatment (Figure 9.a). Interestingly, 
upon drug removal, surviving ST80/Bortezomib cells were able to regrow at similar 
rates compare with ST80 and Bortezomib single treated surviving cells (Figure 9.b). 
This set of data suggests that ST80/Bortezomib surviving cells can activate a defense 





Figure 9: ST80/Bortezomib surviving cells are able to regrowth upon drug removal. 
Cells were treated for 48 hours (day 0) with 20 nM (RD) or 50 nM (RMS13) Bortezomib +/- 50 µM ST80. (a) Cell viability was 
measured by crystal violet assay after 48 hours. Data are expressed as fold change vs. untreated. (b) Cell regrowth was measured at 
indicated time points of the recovery period by crystal violet assay. Data are expressed as fold change vs. day 0. Mean of three 
independent experiments in triplicate is shown. t-Student test was used to determine statistical significance: * p<0,05; **p<0,01.  
 
 
4.2. ST80/Bortezomib surviving cells accumulate protein aggregates upon co-
treatment. 
To understand if ST80/Bortezomib surviving cells show a similar extent of 
proteotoxicity compared to single treated surviving cells, we determined the amount of 
protein aggregates after 48 hours treatment (Figure 10). Protein aggregates are insoluble 
in Triton-X and, due to proteasome inhibition mediated by Bortezomib, are mostly 
ubiquitin-tagged. Surprisingly, ST80/Bortezomib surviving cells show higher amount of 
ubiquitin positive aggregates after fractionation in 2% Triton-X buffer compared both 
with ST80 and Bortezomib single treated surviving cells. Moreover, increase levels of 
p62 are detectable in the insoluble fraction of ST80/Bortezomib surviving cells (Figure 
10.a). p62 is a scaffold protein which posses a UBA and a LIR domain: these domains 
confer to the protein the capability to interact respectively with ubiquitin and LC3. Due 
to this, p62 acts as a “bridge” between aggregates and autophagosomes mediating 




To further confirm protein aggregates accumulation, filter trap assay showed increase 
ubiquitin staining in ST80/Bortezomib surviving cells (Figure 10.b). Aggregates can be 
detected by filter trap assay due to their high molecular weight: vacuum blotting of cell 
lysate performed in non-denaturant conditions will let small molecular weight protein 
pass through the membrane but not high weight multiprotein aggregates that can be 
then detected by western blot analysis (Figure 10.b). Taken together, these data point to 
increase accumulation of protein aggregates in ST80/Bortezomib surviving cells.  
 
 
Figure 10: ST80/Bortezomib surviving cells show accumulation of protein aggregates. 
Cells were treated for 48 hours with 20 nM (RD) or 50 nM (RMS13) Bortezomib +/- 50 µM ST80. (a) Ubiquitin-positive protein 
aggregates were assessed by western blot analysis after fractionation of total viable cells in Triton-X. GAPDH and Histone 3 were 
used as loading and purity controls for soluble and insoluble fractions, respectively. (b) Ubiquitin positive aggregates were detected 
by filter trap assay of viable cells. 
 
 
To exclude that protein aggregates accumulation was due to a general autophagy 
impairment mediated by the co-treatment; we measured LC3 conversion and lysosomal 
acidification in single and double treated surviving cells (Figure 11). During the 
autophagic flux, LC3 is processed into its lipid-conjugated isoform (LC3 II) which 
associates with autophagosome membranes: to monitor LC3 II accumulation by western 
blot analysis is, nowadays, the most used and described method in order to detect 
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autophagy in vitro [133]. As shown in Figure 11.a, ST80/Bortezomib surviving cells 
show similar or even more LC3 II compared with Bortezomib single treated cells, 
suggesting ongoing autophagy. Because accumulation of LC3 II can be caused both by 
induction of autophagy and by blockage of the autophagic flux, we quantified lysosome 
acidification by FACS measurement of Lysotracker Red (LTR) stained cells (Figure 
11.b and c). Lysosomal acidification is a crucial step to finalize the digestion of the 
autophagosome cargo: loss of lysosome acidification results in blockade of the 
autophagy flux. Due to this, the measure of the acidity of the lysosomal compartment is 
an indirect method to quantify autophagy [133]. ST80/Bortezomib surviving cells show 
similar amount of acidic lysosome compared with Bortezomib treated cells during all 
48 hours of drug treatment (Figure 11.c).  
 
Figure 11: ST80/Bortezomib surviving cells undergo bulk autophagy. 
Cells were treated with 20 nM (RD) or 50 nM (RMS13) Bortezomib +/- 50 µM ST80. (a) LC3 I/LC3 II conversion was monitored 
by western blot analysis of viable cells after 48 hours treatment. -Actin was used as loading control. (b-c) Lysosome acidification 
was measured by FACS analysis of Lysotracker Red staining of viable cells after 48 hours (in b) and over time (indicated time 




Taken together, these data show that after 48 hours treatment ST80/Bortezomib 
surviving cells undergo high proteotoxic stress compared to Bortezomib treated cells 
due to the accumulation of ubiquitin-positive protein aggregates which can not be 
cleared by the ongoing bulk autophagy.     
 
4.3. ST80/Bortezomib surviving cells up-regulate co-chaperone BAG3 in a NFB-
dependent manner. 
ST80/Bortezomib co-treatment inhibits simultaneously the two main branches of 
constitutive PQC, i.e. UPS and HDAC6 mediated aggresome-autophagy system. Since 
ST80/Bortezomib surviving cells show enhance accumulation of protein aggregates 
although they are still competent towards bulk autophagy (Figure 10 and 11), we 
hypothesized that an inducible rescue mechanism would be activated in those cells by 
the co-treatment in order to mitigate proteotoxicity. Co-chaperone BAG3 has been 
described to be induced upon proteasome inhibition, i.e. aging process [77]: BAG3 can 
theoretically compensate HDAC6 loss of activity and restore protein aggregates 
recognition by the autophagic machinery triggering their clearance [76]. In order to 
understand if BAG3 plays a role in ST80/Bortezomib surviving cells observed cell 
recovery (Figure 9), we quantified BAG3 mRNA and protein levels in the living RMS 






Figure 12: RMS ST80/Bortezomib surviving cells up-regulate co-chaperone BAG3. 
Cells were treated with 20 nM (RD, BJ) or 50 nM (RMS13, TE671) +/- 50 µM ST80 for 48 hours. mRNA levels were assessed by 
qRT-PCR. Mean of three independent experiments in triplicate is shown.  Protein levels were assessed by western blot; -Actin was 
used as loading control.  
 
 
Interestingly, both BAG3 mRNA and protein levels are highly increased upon 
ST80/Bortezomib cotreatment in all RMS cell lines (Figure 12.a-c). Some increase in 
BAG3 mRNA and protein levels is also detectable upon Bortezomib single treatment, 
in line with previous publications [84]. Moreover, the BJ cell line, which shows no 
further sensitization toward ST80/Bortezomib co-treatment (Figure 7), have no 
transcriptional or translational induction of BAG3 in the ST80/Bortezomib surviving 
population (Figure 12.d). Previous data demonstrate that the co-chaperone BAG1 is 
implicated in proteasomal degradation of misfolded proteins [134]; to assure the 
specificity of BAG3 up-regulation we measured concomitantly BAG1 mRNA levels in 
the living population, showing no changes compared to untreated cells (Figure 12). 
Kinetic analysis of BAG3 mRNA levels underlined a late up-regulation starting 
between 30-42 hours after ST80/Bortezomib co-treatment, in line with the hypothesis 
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that BAG3 plays a major role during the recovery phase and not in the initial phase of 
the treatment (Figure 13). 
 
 
Figure 13: ST80/Bortezomib surviving cells show slow kinetic of BAG3 up-regulation. 
Cells were treated with 20 nM (RD) or 50 nM (RMS13) and 50 µM ST80 for indicated time points. mRNA levels were assessed by 
qRT-PCR. Mean of three independent experiments in triplicate is shown.     
 
To exclude that BAG3 transcriptional up-regulation is simply an unspecific effect of 
massive cell death, we treated the RD cell line with two prototypic apoptotic stimuli 
and measured BAG3 mRNA levels in the surviving population (Figure 14). The TRAIL 
receptor 2 agonistic antibody, Lexatumumab, triggers apoptosis in RMS cell lines via 
death receptor (extrinsic pathway) [135]; the BH3 mimetic ABT-737 leads to cell death 
via the mitochondrial pathway, also known as intrinsic apoptotic pathway [136]. As 
shown in figure 14.a, induction of apoptosis by Lexatumumab and ABT-737 is 
comparable with ST80/Bortezomib co-treatment. Interestingly, no induction of BAG3 
mRNA can be detected in Lexatumumab or ABT-737 surviving population, pointing to 
specificity of BAG3 transcriptional induction by ST80/Bortezomib co-treatment (Figure 
14.b). No changes were detected in BAG1 mRNA levels (Figure 14.b)  
 
Figure 14: BAG3 up-regulation is a specific feature of ST80/Bortezomib treatment. 
RD cell line was treated with 5 µg/ml Lexatumumab or 5 µM ABT-737 for 24 hours. (a) Apoptosis was determined by FACS 
analysis of DNA fragmentation of propidium iodide stained nuclei. (b) BAG1 and BAG3 mRNA levels were assessed with qRT-
PCR. Mean of three independent experiments in triplicate is shown.      
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Recent evidences demonstrate that in a HeLA cell line heat shock model, BAG3 up-
regulation was mediated by NFB [137]. To address the role of NF-B in our model, 
we create RMS cell lines with a phosphomutant IB (IB-SR) which can not be 
phosphorylated on Serine 32 and 36 and consecutively degraded (Figure 15.a). 
Impairing IBdegradation leads to incompetent NFB cell lines [138]; as shown in 
figure 15.b, TNF mRNA induction is completely abolished in IB-SR cells while is 
highly present in the empty vector (EV) cell line after TNF stimulation.  
 
 
Figure 15: IB-SR cells are insensitive to TNF stimulation. 
RMS cells stably expressing empty vector (EV) or IB super repressor vector (IB-SR) were treated with TNF 20 ng/mL for 
2h. (a) IB protein levels were determined by western blot analysis. Tubulin was used as loading control. (b) TNF mRNA levels 
were assessed by qRT-PCR. Mean of two different experiment performed in triplicate is shown.  
 
Interestingly, induction of BAG3 mRNA and protein levels is completely abolished in 
the IB-SR cells after ST80/Bortezomib co-treatment, while still present in the EV 
cell lines (Figure 16). Further studies need to be done to assess the exact role of NF-B 




Figure 16: NF-B mediates BAG3 up-regulation in ST80/Bortezomib surviving cells. 
Cells stably expressing empty vector (EV) or IB super repressor vector (IB-SR) were treated with 20 nM (RD) or 50 nM 
(RMS13) Bortezomib and 50 µM ST80 (BS). (a) BAG1 and BAG3 mRNA levels were determined by qRT-PCR. Mean of two 
independent experiment performed in triplicate is shown. (b) Protein levels were determined by western blot analysis. GAPDH was 
used as loading control.  
 
Taken together, these results demonstrate that ST80/Bortezomib surviving cells 
strongly and specifically induce BAG3 at transcriptional and translational level in a NF-
B dependent manner. 
 
4.4. BAG3 mediates protein aggregates clearance during cell recovery. 
Since BAG3 has been previously reported to mediate protein aggregates clearance via 
selective autophagy [139], we created stable RMS BAG3 knock-down cells by short-
hairpin RNA (shRNA) vectors in order to understand BAG3 role in modulating 
proteotoxicity upon ST80/Bortezomib treatment. As control we used a RNA sequence 
with no corresponding counterpart in the human genome (Figure 17). All three 
sequences against BAG3 mediate loss of basal and ST80/Bortezomib induced up-
regulation of BAG3, both at protein and mRNA levels, while control cells (shCtrl) 
remain able to trigger BAG3 up-regulation up to day 3 of the recovery period (Figure 
17.a and b). Constitutive BAG3 knock-down shows no effect on BAG1 mRNA level 
demonstrating no compensatory mechanism triggered by the loss of BAG3 in these 





Figure 17: shBAG3 cells are unable to up-regulate BAG3 after ST80/Bortezomib treatment. 
RD and RMS13 were stably transfected with three different sequences against BAG3 (shBAG3) and one control (shCtrl). (a) Cells 
were treated with 20 nM (RD) or 50 nM (RMS13) Bortezomib and 50 µM ST80 (BS) for 48 hours (day 0) before treatment was 
removed and cells were grown in drug-free medium up to three days. BAG3 protein levels were assessed by western blot analysis at 
indicated time points. GAPDH was used as loading control. (b-c) Cells were treated with 20 nM (RD) or 50 nM (RMS13) 
Bortezomib and 50 µM ST80 (BS) for 48 hours. BAG1 and BAG3 mRNA levels were assessed by qRT-PCR. Mean of three 
independent experiment performed in triplicate is shown. 
 
 
In line with the late kinetic of BAG3 up-regulation (Figure 13), BAG3 knock down 
RMS cells show no difference in cell death compared with control vector supporting the 
hypothesis that BAG3 is mainly required during the recovery phase, upon drug 





Figure 18: BAG3 is not involved in ST80/Bortezomib induced cell death. 
RD and RMS13 were stably transfected with three different sequences against BAG3 (shBAG3) and one control (shCtrl). Cells 
were treated with 20 nM (RD) or 50 nM (RMS13) Bortezomib +/- 50 µM ST80 for 48 hours. Apoptosis was determined by FACS 
analysis of DNA fragmentation of propidium iodide stained nuclei. Mean of three independent experiments in triplicate is shown. 
 
In order to understand the impact of BAG3 on ubiquitin-positive protein aggregates 
accumulation, we measure Triton-X insoluble aggregates by fractionation of viable 
cells after 48 hours ST80/Bortezomib treatment (day 0; Figure 19.a), and at day 2 and 
day 3 of the recovery period (Figure 19.b). As expected, shBAG3 RMS cell lines show 
no differences compared with control cells in the amount of insoluble ubiquitin-positive 
aggregates and p62 protein levels after 48 hours of ST80/Bortezomib treatment  (day 0 
of recovery) in line with the dispensable role of BAG3 in the initial phase of treatment 
(Figure 19.a). By contrast, at day 2 and day 3 of recovery, loss of BAG3 up-regulation 
determines a striking accumulation of ubiquitin-positive aggregates and p62 protein 
levels in the insoluble fraction (Figure 19.b) compared with control cells. Moreover, 
control cells show decrease ubiquitin-positive aggregates at day 2 and day 3 of recovery 
period when compered to day 0, indicating that BAG3 plays a key role in mitigating 
proteotoxicity by clearing cytotoxic protein aggregates during the recovery phase. To 
further confirm this finding, we evaluate protein aggregates in BAG3 knock down cells 
by filter trap assay (Figure 20). Similarly to Triton-X fractionation, the filter trap assay 
shows increase accumulation of ubiquitin-positive protein aggregates at day 3 of the 
recovery period in shBAG3 cells while control cells show similar levels of protein 
aggregates as in the untreated condition (Figure 20). 
Taken together, these results show that BAG3 up-regulation in ST80/Bortezomib 




Figure 19: BAG3 mediates clearance of protein aggregates during cell recovery. 
RD and RMS13 were stably transfected with three different sequences against BAG3 (shBAG3) and one control (shCtrl). Cells 
were treated with 20 nM (RD) or 50 nM (RMS13) Bortezomib and 50 µM ST80 (BS) for 48 hours (day 0) before treatment was 
removed and cells were grown in drug-free medium up to three days. Ubiquitin-positive protein aggregates were assessed by 
western blot analysis after fractionation of total viable cells in Triton-X after 48 hours (a) and at day 2 and 3 of the recovery period 
(b). GAPDH and Histone 3 were used as loading and purity controls for soluble and insoluble fractions, respectively.   
 
 
Figure 20: BAG3 plays a key role in protein aggregates clearance upon ST80/Bortezomib removal. 
RD was stably transfected with three different sequences against BAG3 (shBAG3) and one control (shCtrl). Cells were treated with 
20 nM Bortezomib and 50 µM ST80 (BS) for 48 hours (day 0) before treatment was removed and cells were grown in drug-free 




4.5. BAG3 is necessary for cell regrowth after ST80/Bortezomib co-treatment. 
In order to investigate the importance of BAG3 up-regulation in mitigation of 
cytotoxicity during the recovery phase, we treated the shBAG3 and control cells for 48 
hours with Bortezomib and/or ST80 (day 0). Then, we removed the treatment allowing 
cells to regrow in drug-free medium up to three days (Figure 21). Untreated and single 
treated surviving cells show comparable ratio of cell regrowth despite the presence or 
absence of BAG3 (Figure 21.a-c), in line with the absence of BAG3 up-regulation 
detected in these conditions (Figure 12.a and c). Contrarily, ST80/Bortezomib shBAG3 
surviving cells completely lost the capability to regrow while shCtrl cells show cell 
regrowth up to three fold at day 3 of the recovery period (Figure 21.d). These data 
suggest that BAG3 up-regulation is necessary for ST80/Bortezomib surviving cells to 
cope with the elevate cytotoxicity induced by the treatment in order to recover upon 
drug removal. 
 
Figure 21: BAG3 up-regulation is necessary for cell regrowth in ST80/Bortezomib surviving cells.  
RD and RMS13 were stably transfected with three different sequences against BAG3 (shBAG3) and one control (shCtrl). Cells 
were treated with 20 nM (RD) or 50 nM (RMS13) Bortezomib and/or 50 µM ST80 for 48 hours (day 0) before treatment was 
removed and cells were grown in drug-free medium up to three days. Cell proliferation was measured by crystal violet staining at 
indicated time points. Data are expressed as fold change vs. day 0. Mean of three independent experiments in triplicate is shown. t-




In order to understand if the loss of viability of shBAG3 cells during the recovery 
period, is due to increase cell death, we measured apoptosis by FACS analysis of 
fragmented DNA after 48 hours of ST80/Bortezomib treatment (day 0 of recovery) and 
at day 3 of the recovery period (Figure 22). BAG3 knock down cells show enhanced 
cell death at day 3 of the recovery period compared with control vector, indicating 
actual cell death of the ST80/Bortezomib surviving cells which are unable to up-
regulate BAG3. 
 
Figure 22: Loss of BAG3 up-regulation triggers cell death during cell recovery. 
RD and RMS13 were stably transfected with three different sequences against BAG3 (shBAG3) and one control (shCtrl). Cells 
were treated with 20 nM (RD) or 50 nM (RMS13) Bortezomib and 50 µM ST80 for 48 hours (day 0) before treatment was removed 
and cells were grown in drug-free medium up to three days. Apoptosis was determined by FACS analysis of DNA fragmentation of 
propidium iodide stained nuclei.  Mean of three independent experiments in triplicate is shown. t-Student test was used to determine 
statistical significance between shBAG3 and control vector or between day 0 and day 3 of the recovery period: **p<0,01. 
 
To understand the long term effects of BAG3 up-regulation, we followed BAG3 knock-
down and control RMS cell lines up to ten days after drug removal (Figure 23.a). 
ST80/Bortezomib surviving cells which are still able to up-regulate BAG3 (shCtrl cell 
lines) show constant cell proliferation after drug removal; on the contrary, cells 
transfected with all three sequences against BAG3 are completely incapable of cell 
regrowth also in longer time periods (Figure 23.a). Then, we wanted to test the role of 
BAG3 in clonogenic survival. To this end, we seeded ST80/Bortezomib surviving cells 
as single cell in drug-free medium and counted the colony number after 14 days (Figure 
23.b-c). Interestingly, BAG3 knock-down cells show significant decrease in colony 
formation compared to control vector although no difference in colony number among 
shBAG3 and control cells was detected for untreated cells, indicating that basal levels 




Figure 23: BAG3 is necessary for long term and clonogenic survival after ST80/Bortezomib removal.  
RD and RMS13 were stably transfected with three different sequences against BAG3 (shBAG3) and one control (shCtrl). (a) Cells 
were treated with 20 nM (RD) or 50 nM (RMS13) Bortezomib and 50 µM ST80 for 48 hours (day 0) before treatment was removed 
and cells were grown in drug-free medium up to ten days. Cell viability was measured at indicated time points by crystal violet 
staining. Data are expressed as fold change vs. day 0.  (b-c) After 48 hours of ST80/Bortezomib treatment cells were seeded as 
single cell and grown in drug-free medium for 14 days. Colonies were visualized by crystal violet staining and counted under the 
microscope. Quantification of the number of colonies (b) and representative images (c) are shown. Mean of three (a) or two (b-c) 
independent experiments in triplicate is shown. t-Student test was used to determine statistical significance between shBAG3 and 
control vector: *p<0,05; **p<0,01. 
 
Taken together, this line of evidences supports the idea that BAG3 is necessary for cell 
regrowth and colony formation during the recovery phase, after ST80/Bortezomib 
removal. 
 
4.6. Impairment of autophagosome formation leads to loss of cell recovery and 
protein aggregates accumulation upon ST80/Bortezomib removal. 
Previous data associated BAG3 mediated clearance of protein aggregates with the 
selective autophagic pathway [71]. In order to understand if BAG3-dependent cell 
recovery upon ST80/Bortezomib removal is mediated by autophagy in our system, we 
created RD inducible ATG7 knock-down cell line (shATG7) (Figure 24.a). Starting 48 
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hours after treatment with doxycycline, ATG7 protein levels markedly decrease in 
shATG7 cells, while ATG7 is still present in the control vector (Figure 24.a). In order 
to exclude any interference of the inducible construct with the initial phase of 
ST80/Bortezomib treatment, we measured apoptosis and cell density after 48 hours of 
drug treatment (Figure 24.b-c). Importantly apoptotic levels and cell surviving ratios are 
comparable between shATG7 cells and control vector, in line with delayed down 
regulation of ATG7 starting 48 hours after doxycycline treatment (Figure 24.a).    
 
Figure 24: Inducible knock down of ATG7 does not interfere with ST80/Bortezomib-induced cell death. 
RD cell line was stably transfected with one sequences against ATG7 (shATG7) and one control (shCtrl). (a) Cells were treated 
with 1 ng/mL doxyciclin for indicated time points. ATG7 protein levels were assessed by western blot analysis. GAPDH was used 
as loading control. (b-c) Cells were treated for 48 hours with 20 nM Bortezomib and 50µM ST80. In (b), apoptosis was determined 
by FACS analysis of DNA fragmentation of propidium iodide stained nuclei. In (c), cell viability was measured by crystal violet 
assay. Data are expressed as fold change vs. untreated. Mean of three independent experiments in triplicate is shown.     
 
Down regulation of ATG7 is maintained up to 120 hours (day 3 of recovery period) and 
leads to impairment of autophagosome formation as shown by the loss of LC3 I/II 
conversion, while control vector maintain ATG7 levels and LC3 I/II conversion ratio 
constant at the same time points (Figure 25.a). In order to understand if the impairment 
of the autophagic pathway, mediated by conditional ATG7 knock-down during the 
recovery phase, leads to accumulation of protein aggregates upon ST80/Bortezomib 
removal, we quantified ubiquitin-positive insoluble aggregates by fractionation of living 
cells in Triton-X (Figure 25.b). Interestingly, impairment of autophagosome formation 
leads to enhance accumulation of ubiquitin-positive aggregates and p62 protein levels 
in the insoluble fraction at day 2 and 3 after drug removal. Control vector cells show 
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decreasing amount of ubiquitin and p62 in the insoluble fraction at day 2 and 3 of the 
recovery period when compared to day 0, while shATG7 cells maintain similar level of 
ubiquitin and p62 protein levels over time, suggesting impairment in protein aggregates 
clearance (Figure 25.b). Moreover, untreated shATG7 cells show higher amount of 
insoluble ubiquitin-positive protein aggregates compared to control vector, underlining 
the importance of the aggresome-autophagy system to maintain protein homeostasis 
also in basal condition (Figure 25.b line 1 and 5 of insoluble fraction).      
 
Figure 25: Impairment of autophagosome formation leads to accumulation of protein aggregates during recovery. 
RD cell line was stably transfected with one sequences against ATG7 (shATG7) and one control (shCtrl). (a) Cells were treated 
with 1 ng/mL doxycycline for indicated time points. LC3 I/II and ATG7 protein levels were assessed by western blot analysis. -
Actin was used as loading control. (b) Cells were treated for 48 hours (day 0) with 20 nM Bortezomib and 50µM ST80 (BS) before 
treatment was removed and cell were grown in drug-free medium up to three days. Ubiquitin-positive protein aggregates and p62 
protein levels were assessed by western blot analysis after fractionation of total viable cells in Triton-X at indicated time points. 
GAPDH and Histone 3 were used as loading and purity controls for soluble and insoluble fractions, respectively. 
 
Accumulation of protein aggregates generally increases cytotoxicity leading to loss of 
cell recovery. To investigate if impairment of autophagosome formation, and  
consequent protein aggregates accumulation upon ST80/Bortezomib removal, leads to 
loss of cell viability, we followed cell proliferation of shATG7 and shCtrl 
ST80/Bortezomib surviving cells up to three days (Figure 26.a). As expected, control 
cells were able to grow in drug-free medium after ST80/Bortezomib removal while 
ATG7 knock down cells proliferation was completely lost. Moreover, shATG7 cells 
show significant increase of fragmented DNA compared to control vector at day 3 of 
the recovering period, indicating cell death during the recovery phase when the 




Figure 26: RD shATG7 cells show loss of cell proliferation and increase apoptosis during recovery.  
RD cell line was stably transfected with one sequences against ATG7 (shATG7) and one control (shCtrl). Cells were treated for 48 
hours (day 0) with 20 nM Bortezomib and 50µM ST80 before treatment was removed and cell were grown in drug-free medium up 
to three days. (a) Cell proliferation was measured by crystal violet staining at indicated time points. Data are expressed as fold 
change vs. day 0. (b) Apoptosis was determined by FACS analysis of DNA fragmentation of propidium iodide stained nuclei. Mean 
of three independent experiments in triplicate is shown. t-Student test was used to determine statistical significance between 
shATG7 and control vector: **p<0,01. 
 
As a side note, we noticed that impairment of autophagosome formation by ATG7 
knock down slightly but significantly decreased cell viability over time in untreated 
conditions compared to control vector (Figure 27).    Although  this basal loss of cell 
viability can not explain the great decrease in cell proliferation of shATG7 cells upon 
ST80/Bortezomib removal (Figure 26.a and 27), this observation points to a critical role 
of the autophagic pathway in RMS cells, in line with previous reports on the role of 
autophagy in tumor maintenance [102, 140]. 
 
Figure 27: Autophagy impairment leads to decrease in cell proliferation in untreated conditions.  
RD cell line was stably transfected with one sequences against ATG7 (shATG7) and one control (shCtrl). Cells were treated for 48 
hours (day 0) with 20 nM Bortezomib and 50µM ST80 (BS) before treatment was removed and cell were grown in drug-free 
medium up to three days. Cell proliferation was measured by crystal violet staining at indicated time points. Data are expressed as 
fold change vs. day 0. Mean of three independent experiments in triplicate is shown. t-Student test was used to determine statistical 




Taken together, this set of evidences demonstrates that the impairment of 
autophagosome formation after ST80/Bortezomib removal, leads to protein aggregates 
accumulation, loss of cell proliferation and increase apoptosis during the recovery 
period similarly to shBAG3 cell lines. 
 
4.7. Impairment of lysosome acidification leads to loss of cell proliferation and 
protein aggregates accumulation upon ST80/Bortezomib removal. 
To further confirm that BAG3 clearance of protein aggregates after ST80/Bortezomib 
removal is mediated by the autophagic pathway, we interfered with the fusion between 
autophagosome and lysosome compartment by impairing lysosomal acidification with 
BafilomycinA1 (BafA1). BafA1 is an inhibitor of lysosomal V-ATPase which is 
responsible for the acidification of the lysosomal compartment: inhibition of 
acidification leads to inactivation of lysosomal enzymes with consequent inhibition of 
autophagosomal-cargo degradation and, finally, autophagy inhibition [133]. We treated 
ST80/Bortezomib surviving RMS cells with or without BafA1 at nanomolar 
concentration up to three days in order to determine protein aggregates by fractionation 
of viable cells in Triton-X (Figure 28). Importantly, BafA1 treated cells show, in the 
insoluble fraction, increase ubiquitin-positive protein aggregates and enhanced p62 
protein levels at day 2 and 3 of the recovery period. 
 
Figure 28: Impairment of the autophagic cargo degradation leads to protein aggregates accumulation during recovery. 
Cells were treated for 48 hours with 20 nM (RD) or 50 nM (RMS13) Bortezomib and 50 µM ST80 (BS) before treatment was 
removed and cells were grown up to three days in fresh medium with or without 5 nM of BafA1. Ubiquitin-positive protein 
aggregates and p62 protein levels were assessed by western blot analysis after fractionation of total viable cells in Triton-X at 





RMS cells supplied with BafA1 after ST80/Bortezomib removal show significantly 
reduced cell growth (Figure 29.a) accompanied by increase apoptosis (Figure 29.b) 
while cells grown in drug-free medium show sustained proliferation and decreased cell 
death. 
Taken together, these results confirmed that inhibition of autophagy leads to 
accumulation of cytotoxic protein aggregates with consequent loss of cell growth and 
increased cell death upon ST80/Bortezomib removal, similarly to RMS cells which are 
not able to up-regulate BAG3 during recovery (Figure 19; 21 and 22). 
 
Figure 29: Impairment of lysosomal degradation results in loss of cell viability and increased cell death upon 
ST80/Bortezomib removal.  
Cells were treated for 48 hours with 20 nM (RD) or 50 nM (RMS13) Bortezomib and 50 µM ST80 before treatment was removed 
and cells were grown up to three days in fresh medium with or without 5 nM of BafA1. (a) Cell proliferation was measured by 
crystal violet staining at indicated time points. Data are expressed as fold change vs. day 0. (b) Apoptosis was determined by FACS 
analysis of DNA fragmentation of propidium iodide stained nuclei. Mean of three independent experiments in triplicate is shown. t-







Finding new strategies to enhance cell death in tumors is the main challenge of 
translational cancer research. Constitutive PQC systems – the UPS and the aggresome-
autophagic system- have recently been suggested to be a promising target in cancer 
therapy [110, 111]. Single drug treatments against proteasome have been demonstrated 
to be just partially effective in tumors, due to compensatory induction of autophagy 
which enhances resistance against proteotoxicity and, in this way, limits cell death [10, 
141, 142]. Thus, combinatory strategies have been proposed to overcome single 
proteasome agent induced resistance: addition of compounds which can inhibit bulk 
autophagy such as chloroquine or 3-MA (3-Methyladenine) have been widely tested in 
the last years in combination with proteasome inhibitors [143, 144].  
HDAC6 has been recently shown to play a key role in the aggresome-autophagic 
system both by recruiting misfolded proteins towards the MTOC, and by mediating 
autophagosome-lysosome fusion via recruitment of a cortactin network [66, 69, 145]. 
Due to its key role in protein aggregates selective autophagy, HDAC6 inhibitors and 
proteasome inhibitors have been tested in combination in various tumor entities, such as 
ovarian, breast or colon carcinoma, showing synergism in cell killing [125, 141, 146].  
Here, we combined a new specific catalytic inhibitor of HDAC6 -ST80- with the FDA-
approved proteasome inhibitor Bortezomib in order to enhance proteotoxicity and 
trigger synergistic cell death in RMS cell lines. We indeed observed increased apoptosis 
upon combination treatment in all tested RMS cell lines but, interestingly, we always 
detected subpopulation of cells which survived ST80/Bortezomib co-treatment and was 
then able to recover, upon drug removal, at the same extent compared to untreated or 
single agent surviving cells. Therefore, we focused our attention on the induced 
compensatory mechanism up-regulated in this subpopulation of cells: we demonstrate, 
for the first time, that co-chaperone BAG3 plays a key role in tumor cell recovery, upon 
drug removal, specifically as a response to acute proteotoxicity triggered by 
concomitant inhibition of constitutive PQC systems. Moreover, we demonstrate that 
BAG3 mediates cell regrowth during cell recovery via selective clearance of cytotoxic 




Figure 30: Scheme of proposed mechanism.  
Inhibition of HDAC6 and proteasome triggers cell death and accumulation of insoluble protein aggregates (red). Surviving cells up-
regulate BAG3 via NFB in order to decrease proteotoxicity by autophagic clearance of protein aggregates therefore stimulating 
cell recovery (green). (See text for details). 
 
Several lines of evidences support this conclusion: first, RMS ST80/Bortezomib 
surviving cells up-regulate massively BAG3 at transcriptional and protein levels while 
Bortezomib surviving cells or surviving cells of well established apoptotic inducers 
show no increase of BAG3 mRNA and/or protein levels (Figures 12 and 14). Similarly, 
non- transformed fibroblast cell line BJ show no increase in BAG3 mRNA and protein 
levels after ST80/Bortezomib treatment pointing to BAG3 up-regulation as a specific 
feature of RMS cells upon acute proteotoxicity. BAG3 up-regulation is mediated by 
NF-B activation: in fact, impairment of NF-B pathway by generation of 
phosphomutant IB RMS cell lines results in complete loss of BAG3 transcriptional 
and translational up-regulation in ST80/Bortezomib surviving cells. Second, BAG3 
knock-down markedly impairs cell growth, clonogenic survival and clearance of 
cytotoxic protein aggregates leading to increased apoptosis upon ST80/Bortezomib 
removal (Figures 19-23). Finally, impairment of the aggresome-autophagy system 
during the recovery phase by inducible ATG7 knock-down or by BafA1 treatment, 
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leads to loss of cell proliferation, accumulation of insoluble protein aggregates and 
increase cell death, similarly to BAG3 knock down cells (Figures 25-26 and 28-29). 
These line of evidences strongly support a model in which BAG3 acts as an on demand 
PQC mechanism engaged by tumor cells upon simultaneous inhibition of constitutive 
PQC systems in order to selectively degrade accumulated protein aggregates and 
stimulate cell recovery upon drug removal.  
Drug-induced resistance is one of the main limitations of efficacy in cancer therapy: 
simultaneous drug targeting of several cell pathways have increased efficacy in tumor 
cell killing, although drug induced resistance still plays a key role in tumor relapse and, 
finally, in the poor prognosis of many tumor types [147-149]. BAG3 has been 
previously described to play an important role in cancer survival by counteracting 
apoptosis. Due to its binding to HSP70, BAG3 is able to retain the pro-apoptotic protein 
BAX in the cytosol thereby preventing BAX translocation to the mitochondria and 
inhibiting cisplatinum- or serum deprivation-induced apoptosis [121]. Moreover, BAG3 
has been described to interfere with HSP70-mediated delivery to proteasome of several 
antiapoptotic proteins such as IKK, BCL2, BCL-XL, mostly by competing with BAG1 
for HSP70 binding [82, 150]. In neuroblastoma cell lines with a defined dependency for 
specific BCL2 family members, BAG3 expression was shown to correlate with MCL-1 
dependency and ABT-737 resistance due to BAG3-mediated protection of MCL-1 
proteasomal degradation in this model [151]. In our study, data suggest that BAG3 does 
not play a key role in preventing apoptosis triggered by ST80/Bortezomib co-treatment 
but acts mainly as a pro-survival mechanism during cell recovery phase through 
modulation of autophagy. We demonstrate a new important function of BAG3 as a pro-
survival protein in cancer aside from its reported role related to modulation of pro- and 
anti-apoptotic proteins. In our model, BAG3 mediates cell recovery by directly 
decreasing the source of stress, i.e. protein aggregates, by selective degradation of 
cytotoxic protein aggregates via autophagy. 
BAG3’s role in selective autophagy has been intensively studied in healthy tissues 
[152]. As a co-chaperone, BAG3 is part of the HSPB8-HSP70-CHIP-BAG3 
multichaperone complex in which it recognizes and binds misfolded proteins in order to 
enhance protein degradation [74, 153]. Also, BAG3 can compensate for HDAC6 
functions in the aggresome-autophagy system by interacting with dynein motors 
promoting the retrograde transport of misfolded proteins along microtubules towards 
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the MTOC [76]. Moreover, BAG3 can interact with the selective autophagic receptor 
p62 linking, in this way, protein aggregates and aggresomes to the autophagic 
machinery via the p62-LC3 interaction on the autophagosomal membranes [77]. Here, 
we show that BAG3 acts as an on demand PQC mechanism engaged in RMS cell lines 
upon intense proteotoxic stress mainly to decrease toxicity during cell recovery through 
its key role in selective autophagy. Interestingly, our data clearly demonstrate that 
inhibition of proteasome by Bortezomib is not sufficient to trigger enhanced BAG3 
transcriptional up-regulation: previous reports showed that inhibition of proteasome-
mediated BAG3 mRNA up-regulation to some extent [154, 155]; however, concomitant 
inhibition of proteasome and of the catalytic activity of HDAC6 triggers, in RMS 
surviving population, a BAG3 mRNA increase of 40-80 fold (Figure 12) depending on 
the cell line, which is higher than the transcriptional up-regulation mediated by single 
Bortezomib treatment. We can speculate that BAG3 on demand activation is related to 
some kind of “proteotoxicity threshold”: the late kinetic of BAG3 up-regulation (30-42 
hours after treatment) in our experiments and the massive increase of BAG3 mRNA in 
ST80/Bortezomib co-treated surviving cells compared to Bortezomib single treated 
cells support this hypothesis.  
BAG3’s engagement in decreasing acute and chronic proteotoxic stress due to 
accumulation of misfolded or damaged proteins has been described previously in 
different models: Nivon and colleagues reported that BAG3 was up-regulated in HeLa 
cells after heat shock and helped coping with the induced proteotoxicity by clearing 
protein aggregates via autophagy [137]. Furthermore, BAG3-mediated selective 
autophagy has been related to modulation of misfolded proteins in neurodegenerative 
disease [153]: HSPB8-BAG3 complex was found up-regulated in astrocytes taken from 
post mortem brains of Alzheimer's, Parkinson's and Huntington's diseases patients, 
pointing to a role of the complex in clearing protein aggregates released from neurons 
and cellular debris. In healthy condition, chronic proteotoxic stress occurs during aging 
[77]: a BAG1/BAG3 switch has been described to occur in an aging cell line model 
correlating with decreased activity of BAG1-mediated proteasome degradation and 
enhanced dependency of PQC on the BAG3-mediated aggresome-autophagy system. 
Moreover, a recent study on the apoptotic transcriptome of mature MII oocyte of aged 
women compared to young women showed that BAG3 is up-regulated in the first group 
underlining the importance of this co-chaperone as a stress response element activated 
during prolonged proteotoxic stress occurring during aging [156].  Those data suggest 
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that the engagement of BAG3, mediated by its transcriptional induction, is needed when 
the level of misfolded or damaged proteins are abruptly increased or constantly 
elevated. Our work adds insights to this general concept: we discovered that 
pharmacological inhibition of PQC systems triggers proteotoxic stress which leads to 
BAG3 induction. In this context, BAG3 plays a key role in mediating tumor cell growth 
and clonogenic survival which can enhance the risk of tumor relapse. The present study 
strengthens the idea of a general context where BAG3 is an on demand mechanism 
engaged by cells when the “proteotoxicity threshold” is exceeded expanding the 
concept from a disease-related condition to a new side effect of proteotoxic cancer 
therapy. In line with our data, BAG3 up-regulation has been linked with NF-B 
activation [137, 157]: the implications of this finding must be further analyzed in order 
to understand which role NF-B precisely plays in the regulation of the on demand 
response towards proteotoxic stress in cancer. 
Enhanced expression of BAG3 has been reported in several tumors such as leukemia 
[120], neuroblastoma [158], pancreatic carcinoma [159], colon carcinoma [160] and 
melanoma [161]. Mainly, increased expression of BAG3 is correlated with poor 
prognosis due to enhanced resistances toward apoptosis: for example, a study on 346 
patients affected by pancreatic adenocarcinoma showed that tumors with enhanced 
BAG3 expression had significant higher aggressiveness compared to tumors that 
express lower levels of BAG3, resulting in poorer prognosis of the patients [162]. 
Moreover, the same study showed that BAG3 mediates decreases sensitivity towards 
gemcitabine treatment in vitro [162]. In addition, BAG3 has been described to play a 
crucial role in cell adhesion and motility pointing to a role in metastasis [163]. PKC 
specific phosphorylation on Ser187 of BAG3 has been described to mediate epithelial-
mesenchymal transition (EMT) in a thyroid carcinoma cell line [81]. EMT is a crucial 
process needed by cancer cells to gain invasiveness and form metastasis: BAG3’s role 
in EMT suggests its involvement in promoting metastatic behavior thereby enhancing 
tumor invasiveness. In this context, our data on the role of BAG3 in clonogenic growth 
of ST80/Bortezomib surviving RMS cell lines gain new importance: our findings 
highlight that therapeutic strategies which enhance proteotoxicity as the main stress for 
apoptosis induction, trigger high BAG3 protein levels in the surviving population which 
might play a crucial role not only in cell regrowth but also in tumor invasiveness 
through BAG3 involvement in EMT promotion. More studies need to be done in order 
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to understand if cells which survive ST80/Bortezomib co-treatment are indeed able to 
migrate and/or invade more than untreated cells. 
Importantly, BAG3 has been reported to be expressed at low levels in young healthy 
cells and to increase during aging in normal conditions [71]. RMS is mainly a 
childhood disease with peak between one and five years [164]: we can speculate that 
BAG3 protein levels in RMS patients are relatively low in healthy cells enhancing the 
possibility of creating effective selective inhibitors towards BAG3 with low side effects 
on non-tumor tissues.  
Interestingly, we demonstrate that BAG3 up-regulation is mediated by NF-B 
activation: this finding opens new interesting question on the regulation of the NF-B 
pathway when proteasome is inhibited. Also, NF-B regulation of BAG3 highlights a 
new pro-survival role of this transcriptional factor in tumors: not only NF-B mediates 
tumor maintenance in stress condition [165] but plays an important role in recovery of 
surviving cells upon drug removal by the induction of pro-survival genes, such as 
BAG3, during the recovery phase. Our data suggest that NF-B plays a role in tumor 
recovery after drug treatment against constitutive PQC systems, but more detailed 
studies must be done to elucidate the detailed contribution of this transcription factor in 
this context. 
Finally, BAG3 has been reported to be present in the hematopoietic stem cell vascular 
niche: silencing of BAG3 in this compartment results in loss of the hematopoietic stem 
cells [166]. This finding suggests that BAG3 might play some role in the maintenance 
of the microenvironment needed for cancer stem cell survival enhancing the importance 
of this protein in cancer survival and propagation. The possibility that BAG3 up-
regulation in ST80/Bortezomib surviving cells could mediate an increase in cancer stem 
like population is intriguing: more studies need to be done to validate this possibility. 
In conclusion, our study provides solid data on a novel role of BAG3 as the key 
mediator of an on demand PQC mechanism which is activated in surviving RMS cells 
upon ST80/Bortezomib co-treatment: BAG3 decreases cytotoxic aggregates by 
selective degradation via the aggresome-autophagy system thereby increasing cell 
proliferation and clonogenic survival. Moreover, we showed that BAG3 can overcome 
the loss of HDAC6 activity in ST80/Bortezomib surviving cells by taking over 
HDAC6’s role in the aggresome-autophagy pathway. The present study also points out 
that combination strategies which simultaneously target the two main branches of 
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constitutive PQC, although enhancing induction of apoptosis, trigger an inducible 
rescue mechanism that, if not impaired, enable surviving cell to proliferate and possibly 
cause relapse. In this context, the evidences here reported suggest that more studies 
need to be done in vitro and in vivo in order to understand the inducible resistance 
mechanisms triggered by co-treatment approaches, specifically related to combination 
of drugs which intensively enhance proteotoxicity. Through the identification of the 
BAG3-mediated selective autophagy pathway as a novel mechanism of acquired 
resistance to compensate concomitant inhibition of the constitutive PQC systems, we 
add a new important piece of evidence on the biological compensatory regulation of 
PQC systems in cancer. We propose that the impairment of this inducible escape 
mechanism may potentiate the efficacy of co-treatment of inhibitors which target the 
protein degradations pathways: to this end, inhibition of both inducible and constitutive 






Summary (Deutsche Zusammenfassung). 
BAG3 Induktion wird benötigt um proteotoxischen Stress nach der Inhibition von 
konstitutiver Proteindegradation durch selektive Autophagie zu vermindern. 
 
Proteinqualitätskontrollsysteme (PQK) sind ein interessanter Ansatzpunkt für die 
Weiterentwicklung von Krebstherapien [9]. In eukaryotischen Zellen sind zwei 
konstitutive Hauptkontrollsysteme bekannt, das unfolded protein response system 
(UPS) und das Aggresome/Autophagie System. Das UPS vermittelt die Ubiquitinierung 
und Degradierung linearer falsch-gefalteter Proteine durch das 26S Proteasom [132]. 
Das Aggresome/Autophagie System ist ein selektiver Autophagieprozess in welchem  
unlösliche und potentiell toxische Proteinaggregate degradiert werden. Hier wird die 
Autophagiemaschinerie zusammen mit spezifischen Proteinadaptoren, welche die 
Erkennung und die spezifische lysosomale Degradierung der Zielporteine vermitteln, 
verwendet [70]. 
Autophagie ist ein dynamischer katabolischer Prozess. Durch Bildung eines 
Doppelmembran ummantelten Vesikels, des Phagophores, welches mit spezifischen 
Autophagiemarkern angereichert ist, hier ist vor allem LC3 zu nennen, wird 
zytosolisches Cargo umschlossen und es bildet sich das Autophagosom. Letztendlich 
fusioniert das Autophagosom mit sauren Lysosomen, das Autophagolysosom, in 
welchem das Cargo in seine basalen Komponenten verdaut wird, welche, z.B. unter 
Stressbedingungen als Nährstoffquelle verwendet werden können  [25]. Obwohl 
Autopagie initial als unspezifischer Mechanismus beschrieben wurde, hat die 
Entdeckung von speziellen Proteinadaptoren gezeigt, dass Autophagie auch ein 
spezifischer Prozess sein kann [39]. p62 ist der erste beschriebene Rezeptor für 
selektive Autophagie ubiquitinierter Proteinaggregate. p62 hat eine 
Ubiquitinbindungsdomäne (UBA) und eine LC3 Interaktionsregion (LIR), welche ihm 
ermöglichen Ubiquitin-positive Proteinaggegrate und Autophagie Membranen 
miteinander zu verbinden [44].  
Histondeacetylase 6 (HDAC6) ist eine zytosolische Deacetylase welche die 
Deacetylierung von α-Tubulin vermittelt. Weiterhin spielt HDAC6 eine vorherrschende 
Rolle in PQK, da es verschiedene Funktionen innerhalb des Aggresome/Autophagie 
Systems innehat. Einerseits erkennt HDAC6 Ubiquitin-markierte Proteine durch seine 
BUZ Domäne (Ubiquitin-bindende Domäne), und ermöglicht deren Aggregation durch 
Dynein-vermittelten retrograden Transport entlang der Mikrotubuli in Richtung der 
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Mikrotubulus organisierenden Zentrums (MTOC) [66]. Andererseits rekrutiert HDAC6 
ein Cortactin Netzwerk, welches für die Autophagosom-Lysosom-Fusion während der 
Autophagie von Proteinaggregaten benötigt wird, aber für Nährstoffentzug-induzierte 
Autohagie erlässlich ist [69]. In beiden Fällen wird die katalytische deacetylierende 
Aktivität von HDAC6 benötigt.  
Proteasominhibitoren des 26S Proteasoms, wie z.B. Bortezomib, und katalytische 
Inhibitoren von HDAC6 können synergistisch Zelltod in Tumoren, wie z.B. 
Ovarialkarzinom [125] induzieren. Durch die simultane Inhibition von zwei 
Hauptsystemen der PQK entsteht erhöhter proteotoxischer Stress welcher letztendlich 
zur Induktion von Apoptose führt.  
Rhabdomyosarkome (RMS), die häufigsten Weichgewebe Tumore bei Kindern, sind 
sensitiv gegenüber Bortezomib Behandlung [112]. Diese Arbeit beruht auf der 
Hypothese, dass die Inhibition des Aggresome/Autophagie Systems, durch einen 
HDAC6 spezifischen katalytischen Inhibitor ST80 [117], zusammen mit Bortezomib 
Behandlung den Zelltod in RMS verstärken kann.  
Wie erwartet konnte durch die gleichzeitige Inhibtion beider Systeme die DNA 
Fragmentierung in allen getesteten RMS Zelllinien erhöht werden. Allerdings konnte 
eine resistente Subpopulation identifiziert werden, welche die Behandlung überlebte 
und sich vergleichbar zu unbehandelten Zellen erholte. 
Unser Ziel war es den molekularen Mechanismus, der dieser Resistenz zugrunde liegt, 
zu identifizieren. Hier konnten wir das Co-Chaperon BAG3 als Hauptmediator dieser 
Erholung nach der Bortezomib/ST80 Behandlung identifizieren. BAG3 vermittelt die 
Degradation von zytotoxischen Proteinaggregaten durch die Induktio von selektiver 
Autophagie.  
Dieser Effekt konnte auf verschiedenen Ebenen bewiesen werden. Einerseits zeigen 
überlebende Zellen erhöhte BAG3 Spiegel, sowohl auf transkriptioneller als auch 
translationeller Ebene, beginnend 30 Stunden nach der Behandlung. Dieser Effekt wird 
bis zu drei Tagen während der Erholungsphase aufrechterhalten. Zudem werden die 
innerhalb dieser drei Tage durch die Doppelbehandlung entstandenen Ubiquitin-
positiven zytotoxischen Aggregate nicht abgebaut falls BAG3 durch RNA-Interferenz 
depletiert wird. Weiterhin zeigen die BAG3-depletierten Zellen keine Anzeichen von 
Erholung nach der Entfernung der Behandlung, sondern sterben vermehrt apoptotisch 
und zeigen vermindertes klonogenes Überleben. BAG3 wurde bisher im 
Zusammenhang mit der Induktion von selektiver Autophagie durch verminderte 
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proteasomale Aktivität beschrieben [84]. BAG3 vermittelt die Erkennung und 
Aggregation falsch-gefalteter Proteine und ermöglicht deren autophagosomale 
Erkennung durch direkte Interaktion mit p62 [76]. Überlebende Zellen der 
Bortezomib/ST80 Behandlung zeigen erhöhte Spiegel an unlöslichen Proteinaggregaten 
welche mit p62 Spiegeln positiv korrelieren. Wir vermuteten, dass de BAG3-
vermitteltern Abbau der p62-Ubiquitin-positiven Proteinaggregate durch 
autophagosomale-lysosomale Degradierung vermittelt wird. Daher regulierten wir die 
Autophagieinduktion durch konditionelle RNAi-vermittelte Depletion des Autophagie-
Schlüsselproteins ATG7 oder durch die Inhibition der Autophagosom-Lysosom Fusion, 
durch den Lysosomeninhibitor BafilomycinA1, bis zu drei Tage während der 
Erholungsphase. Diese Inhibition resultierte in einem vergleichbaren Phänotyp wie die 
permantente BAG3 Depletion: Die überlebenden Zellen waren nicht mehr in der Lage 
weiter zu proliferieren, starben vermehrt apoptotisch ab und wiesen Defekte im Abbau 
von Proteinaggregaten auf. Unsere Daten unterstützen die Annahme, dass die Induktion 
proteotoxischen Stress, welcher durch die Interferenz mit den konstitutiven PQK 
Systemen entsteht, einen Überlebensmechanismus aktiviert der durch die 
transkriptionelle Regulation des Co-Chaperons BAG3 gekennzeichnet ist. BAG3 
reaktiviert die Erkennung Ubiquitin-positiver Proteinaggregate durch die Autophagie-
Maschinerie, gefolgt vom Abbau der Aggregate und anschließender Zellproliferation. 
Nivon und Kollegen zeigten [137], dass die BAG3 Hochregulation in einem HeLa 
Hitzeschock Modell NF-κB vermittelt stattfindet. Um diese Möglichkeit auch in 
unserem System zu überprüfen, generierten wir NF-κB defiziente Zellen, welche einen 
Defekt in BAG3 Regulation aufzeigten. NF-κB Inhibition verhinderte die BAG3 
Induktion vollständig in den ST80/Bortezomib Behandlung überlebenden Zellen. In 
zukünftigen Experimenten soll untersucht werden, wie NF-κB während der 
pharmakologischen Inhibition des Proteasoms aktiviert werden kann. Weiterhin soll die 
Rolle dieser Familie von Transkriptionsfaktoren in der Reaktion auf proteotoxischen 
Stress untersucht werden.   
Unsere Arbeit zeigt, dass nach der gleichzeitigen Inhibition des 26S Proteasoms und 
des HDAC6 vermittelten Aggresome/Autophagy Systems, die Induktion des Co-
Chaperons BAG3 unerlässlich für die Erholung von RMS Zellen nach der Behandlung 
ist. Diese Erkenntnisse tragen maßgeblich zu einem verbesserten Verständnis der PQK 
Regulation in Krebszellen bei: Bisher wurde gezeigt, dass die Inhibition einer der 
beiden konstitutiven PQK Signalwege zur vermehrten Aktivierung des anderen Systems 
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führt um besser mit Stresssituationen umgehen zu können [113]. Dieser Mechanismus 
vermittelt Resistenz von Krebszellen gegenüber einer Einzelbehandlung und liefert die 
Rationale für die synergistische Wirkung einer Kombinationsbehandlung wie z.B. 
Bortezomib/ST80. In dieser Arbeit identifizieren wir einen zusätzlichen 
Überlebensmechanimus, durch welchen Krebszellen, in denen die konsitutiven PQKs 
inhibitiert sind, über die Induktion von BAG3-vermitteltern Abbau von 
Proteinaggregaten nicht nur ihr Überleben sichern, sondern auch deren Proliferation 
angeregt wird. 
BAG3 wird in jungem gesundem [164] Gewebe sehr niedrig exprimiert. 
Rhabdomyosarkom ist ein pädiatrischer Tumor, der meistens zwischen dem 1 und 5 
Lebensjahr auftritt. Die Identifikation von BAG3 als wichtige Komponente des 
Erholungsmechanismus nach Inhibition von konstitutiven PQK Systemen, eröffnet die 
Möglichkeit der Entwicklung eines selektiven BAG3 Inhibitors, welcher im jungen 
Gewebe der Patienten, welche nur niedrige BAG3 Spiegel exprimieren,  weniger 
Toxizität aufweisen könnte.  
Die Identifizierung von BAG3-vermittelter selektiver Autophagie als neuen Resistenz 
Mechanismus um simultane Inihibition von konstitutiven Degradierungssignalwegen zu 
kompensieren, könnte maßgeblich zu der Weiterentwicklung aktueller 
Behandlungsstrategien beitragen: So könnte, dass die Inhibition von konstitutiven 
zusammen mit induzierbaren PQKs, die Zelltodinduktion verstärken, die Erholung 
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